Orthofix Medical (OFIX) 10-Q 31 Mar 15 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Mar. 27, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Jun-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Trading Symbol	OFIX
Entity Registrant Name	ORTHOFIX INTERNATIONAL N V
Entity Central Index Key	884624
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		18,754,831

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$28,919	$28,924	$26,369	$30,767
Restricted cash	45,248	23,761
Trade accounts receivable, less allowance for doubtful accounts of $8,971 and $9,111 at June 30, 2014 and December 31, 2013, respectively	63,322	70,811
Inventories	70,902	72,678
Deferred income taxes	40,402	39,999
Prepaid expenses and other current assets	43,886	28,933
Total current assets	292,679	265,106
Property, plant and equipment, net	51,082	54,372
Patents and other intangible assets, net	8,075	9,046
Goodwill	53,565	53,565
Deferred income taxes	22,762	22,394
Other long-term assets	5,834	7,492
Total assets	433,997	411,975
Current liabilities:
Trade accounts payable	15,712	20,674
Other current liabilities	67,382	49,676
Total current liabilities	83,094	70,350
Long-term debt	20,000	20,000
Deferred income taxes	13,325	13,026
Other long-term liabilities	12,367	12,736
Total liabilities	128,786	116,112
Contingencies (Note 16)
Shareholders' equity:
Common shares $0.10 par value; 50,000,000 shares authorized; 18,534,625 and 18,102,335 issued and outstanding as of June 30, 2014 and December 31, 2013, respectively	1,854	1,810
Additional paid-in capital	228,502	216,653
Retained earnings	70,706	73,897
Accumulated other comprehensive income	4,149	3,503
Total shareholders' equity	305,211	295,863
Total liabilities and shareholders' equity	$433,997	$411,975

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for doubtful accounts	$8,971	$9,111
Common shares, par value	$0.10	$0.10
Common shares, authorized	50,000,000	50,000,000
Common shares, issued	18,534,625	18,102,335
Common shares, outstanding	18,534,625	18,102,335

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (loss) (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]
Product sales	$88,579	$85,929	$176,879	$176,170
Marketing service fees	12,406	11,711	24,120	23,749
Net sales	100,985	97,640	200,999	199,919
Cost of sales	25,414	21,884	52,187	47,725
Gross profit	75,571	75,756	148,812	152,194
Operating expenses
Sales and marketing	42,013	44,539	83,184	90,383
General and administrative	17,553	15,181	34,829	33,422
Research and development	6,313	8,551	12,246	14,292
Amortization of intangible assets	661	565	1,245	1,109
Costs related to the accounting review and restatement	2,327		10,633
Total operating expenses	68,867	68,836	142,137	139,206
Operating income	6,704	6,920	6,675	12,988
Other income and expense
Interest expense, net	-492	-455	-960	-997
Other (expense) income, net	363	-1,207	91	3,557
Other income and (expense)	-129	-1,662	-869	2,560
Income before income taxes	6,575	5,258	5,806	15,548
Income tax expense	-3,309	-3,246	-4,488	-7,610
Net (loss) income from continuing operations	3,266	2,012	1,318	7,938
Discontinued operations (Note 15)
Loss from discontinued operations	-5,829	-8,092	-6,623	-12,052
Income tax benefit	1,880	3,069	2,114	4,550
Net loss from discontinued operations	-3,949	-5,023	-4,509	-7,502
Net (loss) income	-683	-3,011	-3,191	436
Net (loss) income per common share-basic:
Net (loss) income from continuing operations	$0.18	$0.11	($0.07)	$0.41
Net loss from discontinued operations	($0.22)	($0.27)	($0.24)	($0.39)
Net (loss) income per common share-basic	($0.04)	($0.16)	($0.17)	$0.02
Net (loss) income per common share-diluted:
Net (loss) income from continuing operations	$0.18	$0.10	($0.07)	$0.41
Net loss from discontinued operations	($0.22)	($0.26)	($0.24)	($0.39)
Net (loss) income per common share-diluted	($0.04)	($0.16)	($0.17)	$0.02
Weighted average number of common shares:
Basic	18,445,348	19,140,520	18,322,185	19,285,004
Diluted	18,621,192	19,270,044	18,435,128	19,483,715
Other comprehensive (loss) income:
Unrealized (loss) gain on cross-currency swap, net of tax	-31	222	72	-96
Foreign currency translation adjustment	198	-711	574	-3,390
Comprehensive loss	($516)	($3,500)	($2,545)	($3,050)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net (loss) income	($3,191)	$436
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	11,516	10,285
Amortization of debt costs	362	360
Amortization of exclusivity agreements	1,467	688
Provision for doubtful accounts	858	2,192
Deferred income taxes	-452	222
Share-based compensation	2,373	3,437
Excess income tax benefit on employee stock-based compensation	-40	-82
Other	-1,390	2,352
Change in operating assets and liabilities:
Trade accounts receivable	6,760	14,825
Inventories	2,234	-11,478
Prepaid expenses and other current assets	-16,245	5,215
Trade accounts payable	-4,959	-3,452
Other current liabilities	18,981	11,795
Long-term assets	-169	-1,494
Long-term liabilities	-231	-1,164
Net cash provided by operating activities	-17,874	34,137
Cash flows from investing activities:
Capital expenditures for property, plant and equipment	-6,138	-12,826
Capital expenditures for intangible assets	-119	-651
Purchase of other investments		-776
Sale of other investments	32
Net cash used in investing activities	-6,225	-14,253
Cash flows from financing activities:
Net proceeds from issuance of common shares	9,520	2,188
Repayment of bank borrowings, net		-16
Changes in restricted cash	-21,406	721
Repurchase of treasury shares		-26,868
Excess income tax benefit on employee stock-based awards	40	82
Net cash used in financing activities	-11,846	-23,893
Effect of exchange rate changes on cash	192	-389
Net increase (decrease) in cash and cash equivalents	-5	-4,398
Cash and cash equivalents at the beginning of the period	28,924	30,767
Cash and cash equivalents at the end of the period	$28,919	$26,369

Summary_of_significant_account

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]
Summary of significant accounting policies	1. Summary of significant accounting policies
	(a) Basis of presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, certain information and note disclosures, normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2014, are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. The balance sheet at December 31, 2013, has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. For further information, refer to the consolidated financial statements and notes thereto contained in the 2013 Form 10-K/A. The notes to the unaudited condensed consolidated financial statements are presented on a continuing basis unless otherwise noted.
	(b) Reclassifications
	The Company has reclassified certain line items to conform to the current year presentation. The reclassifications have no effect on previously reported net earnings or shareholders’ equity.
	(c) Use of estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates including those related to contractual allowances, doubtful accounts, inventories, potential intangible assets and goodwill impairment, income taxes and share based compensation. Actual results could differ from these estimates.
	(d) Foreign currency translation
	The financial statements for operations outside the U.S. are generally maintained in their local currency. All foreign currency denominated balance sheet accounts, except shareholders’ equity, are translated to U.S. dollars at period end exchange rates and revenue and expense items are translated at weighted average rates of exchange prevailing during the year. Gains and losses resulting from the translation of foreign currency are recorded in the accumulated other comprehensive income component of shareholders’ equity.
	(e) Collaborative agreement
	The Company receives a marketing fee through collaboration with Musculoskeletal Transplant Foundation (“MTF”) for Trinity Evolution®, and Trinity ELITE®, for which, the Company has exclusive marketing rights, and VersaShield™ for which we have non-exclusive marketing rights. Under the agreements with MTF, MTF processes the tissues, maintains inventory, and invoices hospitals and surgery centers and other points of care for service fees, which are submitted by customers via purchase orders. MTF is considered the primary obligor in these arrangements and therefore the Company recognizes these marketing service fees on a net basis upon shipment of the product to the customer.
	(f) Recently issued accounting standards
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 supersedes the revenue recognition requirements in Revenue Recognition (Topic 605), and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for the Company in the fiscal year beginning on January 1, 2017, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the effect that adopting this new accounting guidance will have on consolidated results of operations, cash flows and financial position.

Original_and_Further_Restateme

Original and Further Restatement of the Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Original and Further Restatement of the Consolidated Financial Statements	2. Original and Further Restatement of the Consolidated Financial Statements
	In connection with the Company’s preparation of its consolidated interim quarterly financial statements for the fiscal quarter ended June 30, 2014, the Company determined that certain entries with respect to the previously filed financial statements contained in the Original 2013 Form 10-K and the Original 2014 First Quarter Form 10-Q were not properly accounted for under U.S. generally accepted accounting principles (“U.S. GAAP”). As further described below, these additional errors affect the fiscal years ended December 31, 2013, 2012 and 2011, as well as the fiscal quarter ended March 31, 2014. Due to these errors, the Company determined in August 2014 to restate its consolidated financial statements for the fiscal years ended December 31, 2013, 2012 and 2011 (including the interim quarterly periods contained within the fiscal years ended December 31, 2013 and 2012) and the fiscal quarter ended March 31, 2014, and that the previously filed financial statements for these periods should no longer be relied upon. This Report contains restated consolidated interim financial statements for the fiscal quarter and year-to-date periods ended June 30, 2013.
	Contemporaneously with the filing of this Report, the Company is filing (i) an amendment to the Original 2013 Form 10-K (the “2013 Form 10-K/A”), which amendment contains restated consolidated financial statements for the fiscal years ended December 31, 2013, 2012 and 2011, and the quarterly reporting periods contained within the fiscal years ended December 31, 2013 and 2012, (ii) an amendment to the Original 2014 First Quarter Form 10-Q (the “2014 First Quarter Form 10-Q/A”), which amendment contains restated consolidated interim financial statements for the fiscal quarters ended March 31, 2014 and 2013, and (iii) its delayed Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2014 (the “2014 Third Quarter Form 10-Q”), which contains restated consolidated interim financial statements for the fiscal quarterly and year-to-date periods ended September 30, 2013. The corrections of the additional errors in the 2013 Form 10-K/A and the 2014 First Quarter Form 10-Q/A are referred to herein as the “Further Restatement.”
	The Original 2013 Form 10-K reflected a prior restatement of the Company’s consolidated financial statements for the fiscal years ended December 31, 2012 and 2011 and the fiscal quarter ended March 31, 2013, which we refer to herein as the “Original Restatement.” For additional information regarding the Original Restatement, see the 2013 Form 10-K/A.
	Background of Further Restatement
	During the second quarter of 2014, the Company’s management noted that the Company’s bad debt expense for its BioStim strategic business unit (“SBU”) during the first quarter of 2014 was higher than internally budgeted. As a result, the Company’s internal finance department reviewed bad debt expense entries in prior periods. In connection with this review, the Company also further considered its accounting methodology with respect to certain prior revenue adjustments related to uncollectible patient co-pay and self-pay amounts. As further described below, after performing this review, the Company determined that errors existed relating to the accounting for uncollectible patient co-pay and self-pay amounts, and that certain bad debt reserves originally recorded in fiscal years 2011 and 2012 were reversed in incorrect periods in the Original Restatement in connection with the change to sell-through accounting for certain distributors. After analyzing these errors, the Company determined to further restate its financial statements as described in the 2013 Form 10-K/A, the 2014 First Quarter Form 10-Q/A and herein. In addition to these matters, certain other adjustments identified by management, including revisions to inventory reserves, intercompany profit adjustments and accounts receivable reserves, were made to the consolidated financial statements in connection with the Further Restatement, as discussed below.
	Co-Pay and Self-Pay Revenue Adjustments
	A majority of revenue from the Company’s BioStim SBU is derived from third parties, which is subject to change due to contractual adjustments related to commercial insurance carriers, and may include certain patient co-pay amounts. In addition, certain patient purchasers are without insurance, with revenue derived from “self-pay” arrangements. In previously issued financial statements, the Company recorded these co-pay and self-pay amounts as revenue with estimated uncollectible portions being recognized as bad debt expense. Upon further analysis, it was determined that because collectability of co-pay and self-pay amounts was not reasonably assured, the conditions for revenue recognition had not been met and revenue for those amounts should not have been recognized until collected.
	Adjustments to correct the foregoing reduce equally both the Company’s historical net sales and its sales and marketing expense by approximately $0.3 million and $1.8 million for the fiscal quarter ended June 30, 2013 and the six months ended June 30, 2013, respectively. These adjustments have no effect on net income from continuing operations, net income or total assets in any period.
	Bad Debt Timing Adjustments
	In connection with the foregoing, the Company determined to review bad debt expense trends more broadly across all of its business units. As a result of this process, the Company determined that certain bad debt reserves originally recorded in fiscal years 2011 and 2012 were reversed in incorrect periods in the Original Restatement in connection with the change to sell-through accounting for certain distributors. Because the Original Restatement transferred these transactions to sell-through accounting (as opposed to sell-in accounting, which had been used when the original bad debt reserves were recorded), the bad debt reserve was reversed as part of the Original Restatement, as the receivable that was being reserved for was no longer recognized.
	Adjustments to correct this error result in an increase of sales and marketing expense of $1.5 million for the six months ended June 30, 2013. There were no adjustments to the fiscal quarter ended June 30, 2013. These adjustments resulted in no impact to the accounts receivable balance as of December 31, 2013.
	Accounts Receivable Reserve Adjustments
	As part of analyzing collections experience on accounts receivable, the Company identified that it had incorrectly considered certain deferred revenue amounts included in gross accounts receivable when calculating estimated reserves. Specifically, the computation of the contractual allowances and bad debt allowances, which serves to adjust accounts receivable to the estimated collectible amount, incorrectly assumed that some percentage of the deferred amounts would be collected, rather than fully deferring these amounts.
	Adjustments to correct this error resulted in a net decrease in operating income of $0.4 million for the fiscal quarter ended June 30, 2013 and a net increase in operating income of $0.1 million for the six months ended June 30, 2013, respectively.
	This adjustment resulted in a decrease in accounts receivable, net (due to an increase in reserves) as of December 31, 2013 by $4.2 million.
	Intercompany Profit Adjustments
	The Company has two manufacturing facilities which support the inventory needs of other subsidiaries through intercompany sales transactions. These intercompany sales include a profit margin for the selling subsidiary (“intercompany profit”) that is eliminated by the Company as part of its consolidated financial reporting process. The elimination of intercompany profit requires determining the affected net inventory amounts and their related intercompany profit margin to eliminate all intercompany profit, resulting in all inventories being carried at historical cost in the Company’s consolidated financial statements.
	As part of the Original Restatement the Company made certain corrections to prior period excess and obsolete inventory reserves. The effect of these corrections was not properly considered when determining the adjustments needed to eliminate intercompany profits from inventories in the Original Restatement.
	Adjustments to correct this error resulted in an increase to cost of sales of $0.4 million and $0.2 million for the fiscal quarter ended June 30, 2013 and the six months ended June 30, 2013, respectively.
	This adjustment resulted in a decrease in inventory as of December 31, 2013 by $2.6 million.
	Inventory
	Inventory Existence
	As part of the remediation activities that followed the Original Restatement, the Company expanded its procedures in the second quarter of 2014 to validate the existence of field inventory held by independent sales representatives and noted that, in many cases, this inventory had higher rates of missing inventory (“shrinkage”) than previously estimated. To determine whether these higher error rates were pervasive across its field inventory, the Company counted approximately 90% of its field inventory during the third and fourth fiscal quarters of 2014. These counts resulted in the identification of errors relating to previous estimates of shrinkage.
	Adjustments in the Further Restatement to correct these errors, net of the related effect on previously recorded excess and obsolete inventory reserves, resulted in an increase to cost of sales of $0.1 million for both the fiscal quarter ended June 30, 2013 and the six months ended June 30, 2013.
	These adjustments resulted in a decrease in inventory as of December 31, 2013 by $1.0 million.
	Inventory Reserves
	In connection with its remediation efforts associated with the material weakness noted in the Original Restatement related to inventory reserves, the Company concluded that it was not appropriately calculating inventory reserves, including its consideration of demand assumptions for “kits”, which contain a variety of “piece part” components to be used during surgery that have various demand considerations, as well as inventory held by third parties under inventory purchase obligations.
	Adjustments to correct these errors resulted in an increase to cost of sales of $1.2 million and $1.9 million for the fiscal quarter ended June 30, 2013 and the six months ended June 30, 2013, respectively. These adjustments resulted in a decrease to inventory (due to an increase in reserves) as of December 31, 2013 by $14.4 million.
	Other Adjustments
	In addition to the adjustments described above, the Company is correcting certain other items. The impact of correcting these items results in an increase to income before income taxes of $0.1 million for the fiscal quarter ended June 30, 2013, and a decrease to income before income taxes of $0.2 million for the six months ended June 30, 2013.
	The tables below show the effects of the Further Restatement for the fiscal quarter ended June 30, 2013 and the six months ended June 30, 2013. The tax effect of the adjustments is estimated based on the Company’s estimated tax rate.
		Three Months Ended June 30, 2013
					Further Restatement Adjustments by Category
	(U.S. Dollars, in thousands)	Originally			Co-Pay and			Bad Debt			Accounts			Intercompany			Inventory			Other			Total Further			Restated
		Reported in			Self-Pay			Timing			Receivable			Profit									Restatement
		2013			Revenue						Reserve												Adjustments
		Form 10-Q
	Net sales	$	98,280		$	(336	)	$	—		$	(313	)	$	—		$	—		$	9		$	(640	)	$	97,640
	Cost of sales		20,246			—			—			—			363			1,259			16			1,638			21,884
	Gross profit		78,034			(336	)		—			(313	)		(363	)		(1,259	)		(7	)		(2,278	)		75,756
	Operating expenses
	Sales and marketing		44,910			(336	)		—			48			—			—			(83	)		(371	)		44,539
	General and administrative		15,204			—			—			—			—			—			(23	)		(23	)		15,181
	Research and development		8,551			—			—			—			—			—			—			—			8,551
	Amortization of intangible assets		565			—			—			—			—			—			—			—			565
			69,230			(336	)		—			48			—			—			(106	)		(394	)		68,836
	Operating (loss) income		8,804			—			—			(361	)		(363	)		(1,259	)		99			(1,884	)		6,920
	Other income and (expense)		(1,677	)		—			—			—			—			—			15			15			(1,662	)
	Loss before income taxes		7,127			—			—			(361	)		(363	)		(1,259	)		114			(1,869	)		5,258
	Income tax expense		(2,997	)		—			—			126			127			441			(943	)		(249	)		(3,246	)
	Net loss from continuing operations	$	4,130		$	—		$	—		$	(235	)	$	(236	)	$	(818	)	$	(829	)	$	(2,118	)	$	2,012
		Six Months Ended June 30, 2013
					Further Restatement Adjustments by Category
	(U.S. Dollars, in thousands)	Originally			Co-Pay and			Bad Debt			Accounts			Intercompany			Inventory			Other			Total Further			Restated
		Reported in			Self-Pay			Timing			Receivable			Profit									Restatement
		2013			Revenue						Reserve												Adjustments
		Form 10-Q
	Net sales	$	201,653		$	(1,789	)	$	—		$	123		$	—		$	—		$	(68	)	$	(1,734	)	$	199,919
	Cost of sales		45,863			—			—			—			242			2,079			(459	)		1,862			47,725
	Gross profit		155,790			(1,789	)		—			123			(242	)		(2,079	)		391		$	(3,596	)		152,194
	Operating expenses
	Sales and marketing		89,964			(1,789	)		1,455			40			—			—			713			419			90,383
	General and administrative		33,534			—			—			—			—			—			(112	)		(112	)		33,422
Research and development		14,292			—			—			—			—			—			—			—			14,292
Amortization of intangible assets		1,109			—			—			—			—			—			—			—			1,109
		138,899			(1,789	)		1,455			40			—			—			601			307			139,206
Operating income		16,891			—			(1,455	)		83			(242	)		(2,079	)		(210	)		(3,903	)		12,988
Other income and (expense)		2,527			—			—			—			—			—			33			33			2,560
Income before income taxes		19,418			—			(1,455	)		83			(242	)		(2,079	)		(177	)		(3,870	)		15,548
Income tax expense		(7,678	)		—			509			(29	)		85			728			(1,225	)		68			(7,610	)
Net income from continuing operations	$	11,740		$	—		$	(946	)	$	54		$	(157	)	$	(1,351	)	$	(1,402	)	$	(3,802	)	$	7,938
The effects of the Further Restatement on the condensed consolidated balance sheet as of December 31, 2013 are as follows:
	As of December 31, 2013
(Unaudited, U.S. Dollars, in thousands, except share data)	Originally			Further			Restated
	Reported in			Restatement
	2013			Adjustments
	Form 10-Q
Assets
Current assets:
Cash and cash equivalents	$	30,486		$	(1,562	)	$	28,924
Restricted cash		23,761			—			23,761
Trade accounts receivable, less allowances of $9,111 at December 31, 2013		75,567			(4,756	)		70,811
Inventories		90,577			(17,899	)		72,678
Deferred income taxes		33,947			6,052			39,999
Prepaid expenses and other current assets		25,906			3,027			28,933
Total current assets		280,244			(15,138	)		265,106
Property, plant and equipment, net		54,606			(234	)		54,372
Patents and other intangible assets, net		9,046			—			9,046
Goodwill		53,565			—			53,565
Deferred income taxes		18,336			4,058			22,394
Other long-term assets		7,385			107			7,492
Total assets	$	423,182		$	(11,207	)	$	411,975
Liabilities and shareholders’ equity
Current liabilities:
Trade accounts payable	$	20,674		$	—		$	20,674
Other current liabilities		46,146			3,530			49,676
Total current liabilities		66,820			3,530			70,350
Long-term debt		20,000			—			20,000
Deferred income taxes		13,132			(106	)		13,026
Other long-term liabilities		12,736			—			12,736
Total liabilities		112,688			3,424			116,112
Contingencies (Note 16)
Shareholders’ equity:
Common shares $0.10 par value; 50,000,000 shares authorized; 18,102,335 issued and outstanding as of December 31, 2013		1,810			—			1,810
Additional paid-in capital		216,653			—			216,653
Retained earnings		89,332			(15,435	)		73,897
Accumulated other comprehensive income		2,699			804			3,503
Total shareholders’ equity		310,494			(14,631	)		295,863
Total liabilities and shareholders’ equity	$	423,182		$	(11,207	)	$	411,975
The effects of the Further Restatement on the condensed consolidated statement of operations and comprehensive income for the three and six months ended June 30, 2013 are as follows:
	Three Months Ended June 30, 2013
(Unaudited, U.S. Dollars, in thousands, except share and per share data)	Originally			Further			Restated
	Reported in 2013			Restatement
	Form 10-Q			Adjustments
Product sales	$	86,633		$	(704	)	$	85,929
Marketing service fees		11,647			64			11,711
Net sales		98,280			(640	)		97,640
Cost of sales		20,246			1,638			21,884
Gross profit		78,034			(2,278	)		75,756
Operating expenses
Sales and marketing		44,910			(371	)		44,539
General and administrative		15,204			(23	)		15,181
Research and development		8,551			—			8,551
Amortization of intangible assets		565			—			565
		69,230			(394	)		68,836
Operating income		8,804			(1,884	)		6,920
Other income and expense
Interest expense, net		(470	)		15			(455	)
Other expense		(1,207	)		—			(1,207	)
		(1,677	)		15			(1,662	)
Income before income taxes		7,127			(1,869	)		5,258
Income tax expense		(2,997	)		(249	)		(3,246	)
Net income from continuing operations		4,130			(2,118	)		2,012
Discontinued operations (Note 15)
Loss from discontinued operations		(9,154	)		1,062			(8,092	)
Income tax benefit		2,707			362			3,069
Net loss from discontinued operations		(6,447	)		1,424			(5,023	)
Net loss	$	(2,317	)	$	(694	)	$	(3,011	)
Net income (loss) per common share- basic:
Net income from continuing operations	$	0.22		$	(0.11	)	$	0.11
Net loss from discontinued operations		(0.34	)		0.07			(0.27	)
Net income (loss) per common share- basic	$	(0.12	)	$	(0.04	)	$	(0.16	)
Net income (loss) per common share- diluted:
Net income from continuing operations	$	0.21		$	(0.11	)	$	0.1
Net loss from discontinued operations		(0.33	)		0.07			(0.26	)
Net income (loss) per common share- diluted	$	(0.12	)	$	(0.04	)	$	(0.16	)
Weighted average number of common shares:
Basic		19,140,520			—			19,140,520
Diluted		19,270,044			—			19,270,044
Comprehensive loss	$	(2,836	)	$	(664	)	$	(3,500	)
	Six Months Ended June 30, 2013
(Unaudited, U.S. Dollars, in thousands, except share and per share data)	Originally			Further			Restated
	Reported in 2013			Restatement
	Form 10-Q			Adjustments
Product sales	$	177,969		$	(1,799	)	$	176,170
Marketing service fees		23,684			65			23,749
Net sales		201,653			(1,734	)		199,919
Cost of sales		45,863			1,862			47,725
Gross profit		155,790			(3,596	)		152,194
Operating expenses
Sales and marketing		89,964			419			90,383
General and administrative		33,534			(112	)		33,422
Research and development		14,292			—			14,292
Amortization of intangible assets		1,109			—			1,109
		138,899			307			139,206
Operating income		16,891			(3,903	)		12,988
Other income and expense
Interest expense, net		(1,030	)		33			(997	)
Other income		3,557			—			3,557
		2,527			33			2,560
Income before income taxes		19,418			(3,870	)		15,548
Income tax expense		(7,678	)		68			(7,610	)
Net income from continuing operations		11,740			(3,802	)		7,938
Discontinued operations (Note 15)
Loss from discontinued operations		(13,588	)		1,536			(12,052	)
Income tax benefit		4,031			519			4,550
Net loss from discontinued operations		(9,557	)		2,055			(7,502	)
Net income	$	2,183		$	(1,747	)	$	436
Net income (loss) per common share- basic:
Net income from continuing operations	$	0.61		$	(0.20	)	$	0.41
Net loss from discontinued operations		(0.50	)		0.11			(0.39	)
Net income per common share- basic	$	0.11		$	(0.09	)	$	0.02
Net income per common share- diluted:
Net income from continuing operations	$	0.6		$	(0.19	)	$	0.41
Net loss from discontinued operations		(0.49	)		0.1			(0.39	)
Net income per common share- diluted	$	0.11		$	(0.09	)	$	0.02
Weighted average number of common shares:
Basic		19,285,004			—			19,285,004
Diluted		19,483,715			—			19,483,715
Comprehensive loss	$	(1,362	)	$	(1,688	)	$	(3,050	)
The effects of the Further Restatement on the condensed consolidated statement of cash flows for the six months ended June 30, 2013 are as follows:
	Six Months Ended June 30, 2013
(Unaudited, U.S. Dollars, in thousands)	Originally			Further			Restated
	Reported in			Restatement
	2013			Adjustments
	Form 10-Q
Cash flows from operating activities:
Net income	$	2,183		$	(1,747	)	$	436
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		10,209			76			10,285
Amortization of debt costs		360			—			360
Amortization of exclusivity agreement		688			—			688
Provision for doubtful accounts		2,486			(294	)		2,192
Deferred income taxes		222			—			222
Share-based compensation		3,437			—			3,437
Excess income tax benefit on employee stock-based awards		(82	)		—			(82	)
Other		2,296			56			2,352
Change in operating assets and liabilities:
Trade accounts receivable		13,124			1,701			14,825
Inventories		(12,882	)		1,404			(11,478	)
Prepaid expenses and other current assets		9,343			(4,128	)		5,215
Trade accounts payable		(3,452	)		—			(3,452	)
Other current liabilities		8,844			2,951			11,795
Long-term assets		(1,451	)		(43	)		(1,494	)
Long-term liabilities		(1,164	)		—			(1,164	)
Net cash provided by operating activities		34,161			(24	)		34,137
Cash flows from investing activities:
Capital expenditures for property, plant and equipment		(12,826	)		—			(12,826	)
Capital expenditures for intangible assets		(651	)		—			(651	)
Purchase of other investments		—			(776	)		(776	)
Net cash used in investing activities		(13,477	)		(776	)		(14,253	)
Cash flows from financing activities:
Net proceeds from issuance of common shares		2,188			—			2,188
(Repayment of) proceeds from bank borrowings, net		(16	)		—			(16	)
Changes in restricted cash		721			—			721
Repurchase of treasury shares		(26,868	)		—			(26,868	)
Excess income tax benefit on employee stock-based awards		82			—			82
Net cash used in financing activities		(23,893	)		—			(23,893	)
Effect of exchange rate changes on cash		(476	)		87			(389	)
Net decrease in cash and cash equivalents		(3,685	)		(713	)		(4,398	)
Cash and cash equivalents at the beginning of the period		31,055			(288	)		30,767
Cash and cash equivalents at the end of the period	$	27,370		$	(1,001	)	$	26,369

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]
Inventories	3. Inventories
	The Company’s inventories are primarily stated at standard cost, which approximates actual cost determined on a first-in, first-out basis. The Company adjusts the value of its inventory to the extent management determines that the cost cannot be recovered due to obsolescence or other factors. In order to make these determinations, management uses estimates of future demand and sales prices for each product to determine the appropriate inventory reserves and to make corresponding adjustments to the carrying value of these inventories to reflect the lower of cost or market value. In the event of a sudden significant decrease in demand for the Company’s products, or a higher incidence of inventory obsolescence, the Company could be required to increase its inventory reserves, which would increase cost of sales and decrease gross profit.
	Work-in-process and finished products, include material, labor and production overhead costs. Deferred cost of sales result from transactions where the Company has shipped product or performed services for which all revenue recognition criteria have not been met. Once the revenue recognition criteria have been met, both the deferred revenues and associated cost of sales are recognized.
	Inventories were as follows:
	(U.S. Dollars, in thousands)	June 30,		December 31,
		2014		2013
				(Restated)
	Raw materials	$	4,330	$	6,515
	Work-in-process		7,317		6,606
	Finished products		50,699		51,991
	Deferred cost of sales		8,556		7,566
	Total Inventory	$	70,902	$	72,678

Patents_and_other_intangible_a

Patents and other intangible assets	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Patents and other intangible assets	4. Patents and other intangible assets
	(U.S. Dollars, in thousands)	June 30,			December 31,
		2014			2013
	Cost
	Patents	$	35,526		$	34,820
	Trademarks — definite lived		659			620
	Licenses and other		7,248			7,748
			43,433			43,188
	Accumulated amortization
	Patents		(32,772	)		(31,739	)
	Trademarks — definite lived		(509	)		(454	)
	Licenses and other		(2,077	)		(1,949	)
			(35,358	)		(34,142	)
	Patents and other intangible assets, net	$	8,075		$	9,046

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	5. Goodwill
	As a result of the Company’s change in reporting structure in July of 2013, the Company allocated goodwill to each reporting unit, and subsequently evaluated all reporting units, including the Extremity Fixation and Spine Fixation reporting units, for the possible impairment of goodwill. The result of this evaluation was a full impairment of the goodwill allocated to the Extremity Fixation and Spine Fixation reporting units, totaling $19.2 million. As of December 31, 2013 and June 30, 2014, accumulated impairment was $9.8 million for the Extremity Fixation reporting unit and $9.4 million for the Spine Fixation reportable unit. The BioStim and Biologics reportable units have not been impaired. The following table presents the net carrying value of goodwill by reportable segment as of June 30, 2014 and December 31, 2013.
	(U.S. Dollars, in thousands)	June 30,		December 31,
		2014		2013
	BioStim	$	42,678	$	42,678
	Biologics		10,887		10,887
	Total goodwill	$	53,565	$	53,565

Bank_borrowings

Bank borrowings	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]
Bank borrowings	6. Bank borrowings
	The Company had no borrowings and an unused available line of credit of €5.8 million ($8.0 million) at both June 30, 2014 and December 31, 2013, in its Italian line of credit. This line of credit provides the Company the option to borrow amounts in Italy at rates which are determined at the time of borrowing. This line of credit is unsecured.

Longterm_debt

Long-term debt	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]
Long-term debt	7. Long-term debt
	On August 30, 2010, the Company’s wholly-owned U.S. holding company, Orthofix Holdings, Inc. (“Orthofix Holdings”) entered into a Credit Agreement (the “Credit Agreement”) with certain domestic direct and indirect subsidiaries of the Company (the “Guarantors”), JPMorgan Chase Bank, N.A., as Administrative Agent, RBS Citizens, N.A., as Syndication Agent, and certain lender parties thereto.
	The Credit Agreement provides for a five year, $200 million secured revolving credit facility (the “Revolving Credit Facility”), and a five year, $100 million secured term loan facility (the “Term Loan Facility,” and together with the Revolving Credit Facility, the “Credit Facilities”). On January 15, 2015, at the Company’s request, the lenders agreed to reduce the available capacity under the Revolving Credit Facility to $100 million.
	As of June 30, 2014, and December 31, 2013, there was $20 million outstanding under the Revolving Credit Facility. Borrowings under the Credit Facilities bear interest at a floating rate, which is, at Orthofix Holdings’ option, either the London Inter-Bank Offered Rate (“LIBOR”) plus an applicable margin or a base rate (as defined in the Credit Agreement) plus an applicable margin (in each case subject to adjustment based on financial ratios). Such applicable margin will be up to 3.25% for LIBOR borrowings and up to 2.25% for base rate borrowings depending upon a measurement of the consolidated leverage ratio with respect to the immediately preceding four fiscal quarters. As of June 30, 2014, and December 31, 2013, the entire Revolving Credit Facility was at the LIBOR rate plus a margin of 2.50%. The effective interest rate on the Credit Facilities as of June 30, 2014, and December 31, 2013, was 2.7%. Outstanding balances on the Revolving Credit Facility are due on August 30, 2015.
	Borrowings under the Revolving Credit Facility, which may be made in the future, may be used for working capital, capital expenditures and other general corporate purposes of Orthofix Holdings and its subsidiaries. The Guarantors have guaranteed repayment of Orthofix Holdings’ obligations under the Credit Agreement. The obligations of Orthofix Holdings and each of the Guarantors with respect to the Credit Facilities are secured by a pledge of substantially all of the assets of Orthofix Holdings and each of the Guarantors.
	The Credit Agreement, as amended, requires Orthofix Holdings and the Company to comply with coverage ratios on a consolidated basis and contains affirmative and negative covenants, including limitations on additional debt, liens, investments and acquisitions. The Credit Agreement, as amended, also includes events of default customary for facilities of this type. Upon the occurrence of an event of default, all outstanding loans may be accelerated and/or the lenders’ commitments terminated. On August 14, 2013, the Company entered into a Limited Waiver (the “Original Limited Waiver”) with the lenders under the Credit Agreement (the “Lenders”) which waived requirements under the Credit Agreement to deliver quarterly financial statements for the fiscal quarter ended on June 30, 2013, and related financial covenant certificates, until the earlier of (i) March 31, 2014 or (ii) the date that is one day after such financial statements are publicly filed or released. The Company was in compliance with the affirmative and negative covenants at June 30, 2014 and there were no events of default.
	In connection with the Further Restatement and the Company’s delay in filing this Report, on August 14, 2014 the Company entered into a subsequent Limited Waiver with the Lenders which was extended on September 30, 2014, January 15, 2015 and February 26, 2015 (the “Subsequent Limited Waivers”). Under the Subsequent Limited Waivers, the Lenders collectively waived requirements under the Credit Agreement that the Company deliver quarterly financial statements with respect to the fiscal quarters ended June 30, 2014 and September 30, 2014, and related financial covenant certificates, until the earlier of (i) March 31, 2015 or (ii) the date that is one day after such financial statements are publicly filed or released. The Subsequent Limited Waivers also extend the date by which the Company is required to provide certain 2014 fiscal year financial statements until the earlier of (i) one business day following the date that the Company files its Annual Report on Form 10-K for the fiscal year ended December 31, 2014 or (ii) April 30, 2015. In addition, the Subsequent Limited Waivers provided that the Further Restatement would not constitute a default or event of default provided that within one business day after the public release or filing of such restated financial statements, the Company delivered corrected financial statements and compliance certificates with respect to such restated periods and immediately paid any additional interest and other fees that would have been owed had applicable interest and fees originally been calculated based on the restated financial statements. As of the date hereof, the Company has delivered the quarterly consolidated financial statements for the fiscal quarters ended June 30, 2014 and September 30, 2014, and the Company does not expect the Further Restatement to trigger any such additional interest or fees with respect to such prior periods. However, in the event that the Company does not satisfy these respective obligations under the Subsequent Limited Waivers and/or the Credit Agreement, an event of default could be declared under the Credit Agreement, which could have a material adverse effect on the Company’s financial position.
	Certain subsidiaries of the Company have restrictions on their ability to pay dividends or make intercompany loan advances pursuant to the Company’s Credit Facilities. The net assets of Orthofix Holdings and its subsidiaries are restricted for distributions to the parent company. Domestic subsidiaries of the Company, as parties to the credit agreement, have access to these net assets for operational purposes.
	The amount of restricted net assets of Orthofix Holdings and its subsidiaries as of June 30, 2014, and December 31, 2013, is $175.6 million and $168.5 million, respectively. In addition, the Credit Agreement restricts the Company and subsidiaries that are not parties to the Credit Facilities from access to cash held by Orthofix Holdings, Inc. and its subsidiaries. All of the Company’s subsidiaries that are parties to the Credit Agreement have access to this cash for operational and debt repayment purposes. The amount of restricted cash of the Company as of June 30, 2014, and December 31, 2013, was $45.2 million and $23.8 million, respectively.
	In conjunction with obtaining the Credit Facilities and the Credit Agreement, as amended, the Company incurred debt issuance costs of $5 million. These costs are being amortized using the effective interest method over the life of the Credit Facilities. In conjunction with the Term Loan Facility repayment in May 2012, the Company wrote off $0.8 million of related debt issuance costs. As of June 30, 2014, and December 31, 2013, debt issuance costs, net of accumulated amortization, related to the Credit Agreement were $0.8 million and $1.1 million, respectively.

Derivative_instruments

Derivative instruments	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments	8. Derivative instruments
	The tables below disclose the types of derivative instruments the Company owns, the classifications and fair values of these instruments within the balance sheet, and the amount of gain (loss) recognized in other comprehensive income (loss) (“OCI”) or net income (loss).
	(U.S. Dollars, in thousands)	Fair value: favorable			Balance sheet location
		(unfavorable)
	As of June 30, 2014
	Cross-currency swap	$	(863	)		Other long-term liabilities
	Warrants	$	107			Other long-term assets
	As of December 31, 2013
	Cross-currency swap	$	(1,036	)		Other long-term liabilities
	Warrants	$	107			Other long-term assets
		Three Months Ended					Six Months Ended
		June 30,					June 30,
	(U.S. Dollars, in thousands)	2014			2013		2014		2013
	Cross-currency swap and warrants unrealized gain (loss) recorded in other comprehensive income (loss), net of taxes	$	(31	)	$	222	$	72	$	(96	)
	Cross-currency swap
	On September 30, 2010, the Company entered into a cross-currency swap agreement (the “replacement swap agreement”) with JPMorgan Chase Bank and Royal Bank of Scotland PLC (the “counterparties”) to manage its cash flows related to foreign currency exposure for a portion of the Company’s intercompany receivable of a U.S. dollar functional currency subsidiary that is denominated in Euro.
	Under the terms of the swap agreement, the Company pays Euros based on a $28.7 million notional value and a fixed rate of 5.00% and receives U.S. dollars based on a notional value of $39 million and a fixed rate of 4.635%. The expiration date is December 30, 2016, the date upon which the underlying intercompany debt, to which the swap agreement applies, matures. The swap agreement is designated as a cash flow hedge and therefore the Company recognized an unrealized gain (loss) on the change in fair value, net of tax, within other comprehensive income (loss).
	Warrants
	In 2013 and 2014, the Company purchased notes receivable from Bone Biologics, Inc. (“Bone Biologics”) totaling $250 thousand, all of which were issued with detachable warrants to purchase common stock of Bone Biologics. As of June 30, 2014 and December 31, 2013, the Company held warrants for 125 thousand shares of Bone Biologics, at an exercise price of $1.00 per share.
	Under the terms of the note and warrant purchase agreements, the warrants to purchase common stock in Bone Biologics are both detachable from the note, exercisable over a seven year period, and transferable by the holder to other parties. There was no change in fair value of the warrants for the three or six months ended June 30, 2014.

Fair_value_measurements

Fair value measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]
Fair value measurements	9. Fair value measurements
	Fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Non-financial assets and liabilities of the Company measured at fair value include any long-lived assets or equity method investments that are impaired in a currently reported period. The authoritative guidance also describes three levels of inputs that may be used to measure fair value:
	Level 1	—			quoted prices in active markets for identical assets and liabilities
	Level 2	—			observable inputs other than quoted prices in active markets for identical assets and liabilities
	Level 3	—			unobservable inputs in which there is little or no market data available, which require the reporting entity to develop
					its own assumptions
	The Company’s financial instruments include cash equivalents, restricted cash, certificates of deposit, treasury securities, collective trust funds, trade accounts receivable, accounts payable, long-term secured debt, deferred compensation plan liabilities and derivative securities. The carrying value of restricted cash, accounts receivable and accounts payable approximate fair value due to the short-term maturities of these instruments. The Company’s credit facilities carry a floating rate of interest, and therefore, the carrying value is considered to approximate the fair value.
	The Company’s collective trust funds, treasury securities, certificates of deposit, deferred compensation plan liabilities and derivative securities are the only financial instruments recorded at fair value on a recurring basis. The fair value of treasury securities and certificates of deposit are determined based on quoted prices in active markets for identical assets, therefore, the Company has categorized these instruments as Level 1 financial instruments. The cross-currency derivative instrument consists of an over-the-counter contract, which is not traded on a public exchange. The fair value of this derivative swap contract, the common stock warrants, the Company’s collective trust funds and the Company’s deferred compensation plan liabilities are determined based on inputs that are readily available in public markets or can be derived from information available in publicly quoted markets, therefore, the Company has categorized these instruments as Level 2 financial instruments. Changes in the fair value of collective trust funds and deferred compensation plan liabilities are recorded in Other income (expense). The Company also considers counterparty credit risk and its own credit risk in its determination of estimated fair values. The Company has consistently applied these valuation techniques in all periods presented.
	The fair value of the Company’s financial assets and liabilities on a recurring basis were as follows:
	(U.S. Dollars in thousands)	Balance			Level 1		Level 2			Level 3
		June 30,
		2014
	Assets
	Collective trust funds	$	1,685		$	—	$	1,685		$	—
	Treasury securities		678			678		—			—
	Certificates of deposit		1,717			1,717		—			—
	Derivative securities		107			—		107			—
	Total	$	4,187		$	2,395	$	1,792		$	—
	Liabilities
	Deferred compensation plan	$	(1,927	)	$	—	$	(1,927	)	$	—
	Derivative securities		(863	)		—		(863	)		—
	Total	$	(2,790	)	$	—	$	(2,790	)	$	—
	(U.S. Dollars in thousands)	Balance			Level 1		Level 2			Level 3
		December 31,
		2013
		(Restated)
	Assets
	Collective trust funds	$	1,667		$	—	$	1,667		$	—
	Treasury securities		660			660		—			—
	Certificates of deposit		1,562			1,562		—			—
	Derivative securities		107			—		107			—
	Total	$	3,996		$	2,222	$	1,774		$	—
	Liabilities
	Deferred compensation plan	$	(2,506	)	$	—	$	(2,506	)	$	—
	Derivative securities		(1,036	)		—		(1,036	)		—
	Total	$	(3,542	)	$	—	$	(3,542	)	$	—

Accumulated_other_comprehensiv

Accumulated other comprehensive income	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]
Accumulated other comprehensive income	10. Accumulated other comprehensive income
	Accumulated other comprehensive income is comprised of foreign currency translation adjustments, the effective portion of the gain (loss) on the Company’s cross-currency swap, which is designated and accounted for as a cash flow hedge and the unrealized gain (loss) on warrants. The components of and changes in accumulated other comprehensive income were as follows:
	(U.S. Dollars, in thousands)		Foreign		Change in			Accumulated
			Currency		Fair Value			Other
			Translation					Comprehensive
			Adjustments					Income
			(Restated)		(Restated)			(Restated)
	Balance at December 31, 2013		$	3,651	$	(148	)	$	3,503
	Unrealized gain on cross-currency swap and warrants, net of tax			—		72			72
	Foreign currency translation adjustment (1)			574		—			574
	Balance at June 30, 2014		$	4,225	$	(76	)	$	4,149
	-1	As undistributed earnings of non-U.S. dollar denominated foreign subsidiaries are indefinitely reinvested, no deferred taxes are recognized on the related foreign currency translation adjustment.

Earnings_per_share

Earnings per share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]
Earnings per share	11. Earnings per share
	For the three and six months ended June 30, 2014 and 2013, there were no adjustments to net income (loss) for purposes of calculating basic and diluted net income (loss) available to common shareholders. The following is a reconciliation of the weighted average shares used in the basic and diluted net income (loss) per common share computations.
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Weighted average common shares-basic		18,445,348		19,140,520		18,322,185		19,285,004
	Effect of dilutive securities:
	Unexercised stock options net of treasury share repurchase		175,844		129,524		112,943		198,711
	Weighted average common shares-diluted		18,621,192		19,270,044		18,435,128		19,483,715
	Options to purchase shares of common stock with exercise prices in excess of the average market price of common shares are not included in the computation of diluted earnings per share. There were 945,725 and 1,193,425 outstanding options not included in the diluted earnings per share computation for the three and six months ended June 30, 2014, respectively, because the inclusion of these options was antidilutive. There were 1,160,079 and 996,478 outstanding options not included, respectively, in the diluted earnings per share computation for the three and six months ended June 30, 2013, respectively, because the inclusion of these options was anti-dilutive.

Sharebased_compensation

Share-based compensation	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based compensation	12. Share-based compensation
	All share-based compensation costs are measured at the grant date, based on the estimated fair value of the award, and are recognized as expense in the condensed consolidated statements of operations over the requisite service period.
	The following table shows the detail of share-based compensation by line item in the condensed consolidated statements of operations:
		Three Months Ended					Six Months Ended
		June 30,					June 30,
	(U.S. Dollars, in thousands)	2014		2013			2014		2013
	Cost of sales	$	29	$	(563	)	$	58	$	(276	)
	Sales and marketing		429		470			873		906
	General and administrative		657		1,530			1,299		2,705
	Research and development		71		57			143		102
	Total	$	1,186	$	1,494		$	2,373	$	3,437
	On June 30, 2014, the Company granted restricted share awards to executive employees, which vesting is based on achieving earnings targets in two consecutive rolling four quarter periods. In March 2013, the Company granted options to its newly-appointed Chief Executive Officer, which vesting is based on achieving certain market prices for the Company’s common stock.
	During the three and six months ended June 30, 2014, there were 168,715 and 432,290 shares, respectively, of common stock issued related to stock purchase plan issuances, stock option exercises and the vesting of restricted stock awards. During the three and six months ended June 30, 2013, there were 29,479 and 143,444 shares, respectively, of common stock issued related to stock purchase plan issuances, stock option exercises and the vesting of restricted stock awards.

Income_taxes

Income taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Income taxes	13. Income taxes
	The Company recognized a $4.5 million and $7.6 million provision for income tax which reflects an effective tax rate of 77.3% and 48.9% on pre-tax income for the six months ended June 30, 2014, and 2013, respectively. Excluding the impact of various discrete charges, the effective tax rate on continuing operations for the first six months of 2014 and 2013 was 63.2% and 48.8%, respectively. The principal factors affecting the Company’s June 30, 2014, effective tax rate were the Company’s mix of earnings among various tax jurisdictions, state taxes, current period losses in certain jurisdictions for which the Company does not currently provide a tax benefit and variations in the customary relationship between income tax expense and pretax earnings resulting from non-recurring expenses.
	As of June 30, 2014 and December 31, 2013, the Company’s unrecognized tax benefit was $0.8 million. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits in income tax expense. The Company had approximately $0.5 million accrued for payment of interest and penalties as of June 30, 2014, and December 31, 2013. The entire amount of unrecognized tax benefits, including interest, would favorably impact the Company’s effective tax rate if recognized. It is reasonably possible that the amount of the unrecognized benefit with respect to certain of our unrecognized tax positions will significantly increase or decrease within the next 12 months. These changes may be the result of settlements of ongoing audits, competent authority proceedings or other events. At this time, an estimate of the range of the reasonably possible outcomes cannot be made.

Business_segment_information

Business segment information	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]
Business segment information	14. Business segment information
	The Company manages the business by four strategic business units (“SBUs”), which are comprised of BioStim, Biologics, Extremity Fixation, and Spine Fixation supported by Corporate activities. These SBUs represent the segments for which the Chief Executive Officer, who is also our Chief Operating Design Maker (“CODM”) reviews financial information and makes resource allocation decisions among business units. The primary metric used by the CODM in managing the Company is net margin, which is defined as gross profit less sales and marketing expense. The Company neither discretely allocates assets, other than goodwill, to its operating segments nor evaluates the operating segments using discrete asset information. Accordingly, segment information has been prepared based on four SBUs reporting segments. These four segments are discussed below.
	BioStim
	The BioStim SBU manufactures, distributes, and provides support services for market leading devices that enhance bone fusion. These Class Ill medical devices are indicated as an adjunctive, noninvasive treatment to improve fusion success rates in the cervical and lumbar spine as well as a therapeutic treatment for non-spine fractures that have not healed (non-unions). The devices utilize Orthofix’s patented pulsed electromagnetic field (“PEMF”) technology which is supported by strong basic mechanism of action data in the scientific literature as well as strong level one randomized controlled clinical trials in the medical literature. Current research and clinical studies are also underway to identify potential new clinical indications.
	Biologics
	Biologics provides a portfolio of regenerative products that allow physicians to successfully treat a variety of spinal and orthopedic conditions. This SBU specializes in the marketing of regeneration tissue forms. Biologics markets its tissues through a network of distributors, sales representatives and affiliates to supply to hospitals, doctors, and other healthcare providers, primarily in the U.S. The Company’s partnership with Musculoskeletal Transplant Foundation (“MTF”) allows the Company to exclusively market Trinity Evolution® and Trinity ELITE® tissue forms for musculoskeletal defects to enhance bony fusion as well as VersaShield™ for which we have non-exclusive marketing rights.
	Extremity Fixation
	The Extremity Fixation SBU offers products that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. This SBU specializes in the design, development, and marketing of the Company’s orthopedic products used in fracture repair, deformity correction and bone reconstruction. Extremity Fixation distributes its products through a network of distributors, sales representatives, and affiliates. This SBU uses both direct and distributor sales representatives to sell orthopedics products to hospitals, doctors, and other health providers, globally.
	Spine Fixation
	The Spine Fixation SBU specializes in the design, development and marketing of a broad portfolio of implant products used in surgical procedures of the spine. Spine Fixation distributes its products through a network of distributors and affiliates. This SBU uses distributor sales representatives to sell spine products to hospitals, doctors and other healthcare providers, globally.
	Corporate
	Corporate activities are comprised of the operating expenses of Orthofix International N.V. and its holding company subsidiaries, along with activities not necessarily identifiable within the four SBUs.
	The accounting policies of the segments are the same as those described in the business segment information found in Note 13, “Business segment information” to the Consolidated Financial Statements included in the 2013 Form 10-K/A.
	The table below presents external net sales by SBU reporting segment (amounts reported for prior periods have been reclassified to conform to the new segment reporting structure). Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution®, Trinity ELITE® and Versashield™ in the Biologics segment.
		External Net Sales by SBU
		Three Months Ended June 30,
	(U.S. Dollars, in thousands)	2014			2013			Reported			Constant
								Growth			Currency
											Growth
					(Restated)			(Restated)			(Restated)
	BioStim	$	39,513		$	37,948			4	%		4	%
	Biologics		13,853			13,240			5	%		5	%
	Extremity Fixation		27,303			23,210			18	%		14	%
	Spine Fixation		20,316			23,242			(13	)%		(13	)%
	Total Net Sales	$	100,985		$	97,640			3	%		3	%
		External Net Sales by SBU
		Six Months Ended June 30,
	(U.S. Dollars, in thousands)	2014			2013			Reported			Constant
								Growth			Currency
											Growth
					(Restated)			(Restated)			(Restated)
	BioStim	$	76,650		$	75,174			2	%		2	%
	Biologics		26,863			26,600			1	%		1	%
	Extremity Fixation		54,369			49,407			10	%		9	%
	Spine Fixation		43,117			48,738			(12	)%		(12	)%
	Total Net Sales	$	200,999		$	199,919			1	%		—	%
	The table below presents net margin, defined as gross profit less sales and marketing expenses, from continuing operations by SBU reporting segment:
	Net margin by SBU	Three Months Ended						Six Months Ended
		June 30,						June 30,
	(U.S. Dollars, in thousands)	2014			2013			2014			2013
					(Restated)						(Restated)
	Net margin:
	BioStim	$	17,706		$	18,035		$	32,726		$	35,218
	Biologics		6,496			5,706			12,997			11,725
	Extremity Fixation		6,656			5,250			13,590			10,891
	Spine Fixation		3,130			2,708			7,189			4,883
	Corporate		(430	)		(482	)		(874	)		(906	)
	Total net margin		33,558			31,217			65,628			61,811
	General and administrative		17,553			15,181			34,829			33,422
	Research and development		6,313			8,551			12,246			14,292
	Amortization of intangible assets		661			565			1,245			1,109
	Costs related to the accounting review and restatement		2,327			—			10,633			—
	Operating income	$	6,704		$	6,920		$	6,675		$	12,988

Sale_of_Breg

Sale of Breg	6 Months Ended
	Jun. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]
Sale of Breg	15. Sale of Breg
	In May of 2012, the Company sold its subsidiary Breg, Inc. In connection with this sale transaction, the Company agreed to indemnify the buyer with respect to certain specified matters. The portion of the indemnification related to post closing claims related to post-closing sales of cold therapy units has created a guarantee under Accounting Standards Codification ASC 460, Guarantees, and the fair value of the liability has been recorded under the initial recognition criteria in the amount of $2 million at the closing date. The Company is amortizing the fair value of the non-contingent liability ratably over the period of indemnification, which is three years. The Company’s remaining obligations under this guarantee were approximately $0.6 million and $0.9 million as of June 30, 2014 and December 31, 2013, respectively.
	Discontinued operations for the three and six months ended June 30, 2014 is $3.9 million and $4.5 million, respectively, of expense related to the Company’s indemnification of certain specified matters described above.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Contingencies	16. Contingencies
	The Company is party to certain outstanding legal proceedings, investigations and claims. These matters are described in the 2013 Form 10-K/A. As of the end of the period covered by this report, there had been no further material developments with respect to these matters other than as described below.
	As previously disclosed, at the time of its divestiture by the Company in 2012, the Company’s sports medicine subsidiary, Breg, Inc., was currently and had been engaged in the manufacturing and sales of motorized cold therapy units used to reduce pain and swelling. Several domestic product liability cases were filed in recent years, mostly in California state court, alleging that the use of cold therapy causes skin and/or nerve injury and seeking damages on behalf of individual plaintiffs who were allegedly injured by such units. In connection with the Company’s divestiture of Breg, the Company agreed to indemnify Breg’s acquirer for Breg’s pre-closing sales of cold therapy units and certain post-closing sales of cold therapy units. In September 2014, the Company entered into a master settlement agreement that resolves the pending claims with respect to all except one claim pending in a California coordinated proceeding concerning pre-closing sales. Pursuant to the terms of the settlement agreement, the Company paid approximately $1.3 million, and additional amounts owed under the settlement were paid directly by the Company’s insurance providers. These amounts paid by the Company have been recorded as an expense during the fiscal quarter ended June 30, 2014.
	In addition, the Company does not accrue for estimated legal fees and other directly related costs as they are expensed as incurred.

Stock_repurchase_program

Stock repurchase program	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]
Stock repurchase program	17. Stock repurchase program
	On May 8, 2013, the Company announced that its Board of Directors had authorized a share repurchase program in an amount up to $50 million. To date, the Company has made total repurchases in an amount equal to $39.5 million, all of which were made between May and July 2013.

Subsequent_events

Subsequent events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]
Subsequent events	18. Subsequent events
	On August 14, 2014 the Lenders and the Company entered into a subsequent Limited Waiver which was extended on September 30, 2014, January 15, 2015 and February 26, 2015 (the “Subsequent Limited Waivers”). Under the Subsequent Limited Waivers, the Lenders collectively waived requirements under the Credit Agreement that the Company deliver quarterly financial statements with respect to the fiscal quarters ended June 30, 2014 and September 30, 2014, and related financial covenant certificates, until the earlier of (i) March 31, 2015 or (ii) the date that is one day after such financial statements are publicly filed or released. The Subsequent Limited Waivers also extend the date by which the Company is required to provide certain 2014 fiscal year financial statements until the earlier of (i) one business day following the date that the Company files its Annual Report on Form 10-K for the fiscal year ended December 31, 2014 or (ii) April 30, 2015. In addition, the Subsequent Limited Waivers provided that the Further Restatement would not constitute a default or event of default provided that within one business day after the public release or filing of such restated financial statements, the Company delivered corrected financial statements and compliance certificates with respect to such restated periods and immediately paid any additional interest and other fees that would have been owed had applicable interest and fees originally been calculated based on the restated financial statements.
	In January 2015, the Company completed the sale of its Tempus™ Cervical Plate product line, which was part of the Company’s Spine Fixation SBU. The sale included the transfer of net assets of $2.1 million, consisting of intellectual property and the associated inventory, in exchange for consideration of $4.8 million in cash.
	On March 4, 2015, the Company entered into an Option Agreement (the “Option Agreement”) with eNeura, Inc. (“eNeura”), a privately held medical technology company that is developing devices for the treatment of migraines. The Option Agreement provides the Company with an exclusive option to acquire eNeura (the “Option”) during the 18-month period following the grant of the Option. In consideration for the Option, (i) the Company paid a non-refundable $250,000 fee to eNeura, and (ii) eNeura issued a Convertible Promissory Note (the “eNeura Note”) to the Company. The principal amount of the eNeura Note is $15,000,000 and interest will accrue at 8%. The eNeura Note will mature on the earlier of (i) March 4, 2019, or (ii) consummation of the acquisition (as described below), unless converted or prepaid at an earlier date. The Company will be entitled to designate one representative for appointment to the board of directors of eNeura during the 18-month option period. Pursuant to an Agreement and Plan of Merger between the Company, eNeura and certain other parties, if the Company exercises the Option to acquire eNeura, the Company will pay to former eNeura shareholders $65 million (subject to certain positive or negative adjustments based on the assets and liabilities of eNeura). In addition, during the 4-year period following the closing of such acquisition, the Company may be required to pay additional cash consideration to eNeura shareholders upon the satisfaction of certain milestones.

Summary_of_significant_account1

Summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]
Basis of presentation	(a) Basis of presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, certain information and note disclosures, normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2014, are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. The balance sheet at December 31, 2013, has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. For further information, refer to the consolidated financial statements and notes thereto contained in the 2013 Form 10-K/A. The notes to the unaudited condensed consolidated financial statements are presented on a continuing basis unless otherwise noted.
Reclassifications	(b) Reclassifications
	The Company has reclassified certain line items to conform to the current year presentation. The reclassifications have no effect on previously reported net earnings or shareholders’ equity.
Use of estimates	(c) Use of estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates including those related to contractual allowances, doubtful accounts, inventories, potential intangible assets and goodwill impairment, income taxes and share based compensation. Actual results could differ from these estimates.
Foreign currency translation	(d) Foreign currency translation
	The financial statements for operations outside the U.S. are generally maintained in their local currency. All foreign currency denominated balance sheet accounts, except shareholders’ equity, are translated to U.S. dollars at period end exchange rates and revenue and expense items are translated at weighted average rates of exchange prevailing during the year. Gains and losses resulting from the translation of foreign currency are recorded in the accumulated other comprehensive income component of shareholders’ equity.
Collaborative agreement	(e) Collaborative agreement
	The Company receives a marketing fee through collaboration with Musculoskeletal Transplant Foundation (“MTF”) for Trinity Evolution®, and Trinity ELITE®, for which, the Company has exclusive marketing rights, and VersaShield™ for which we have non-exclusive marketing rights. Under the agreements with MTF, MTF processes the tissues, maintains inventory, and invoices hospitals and surgery centers and other points of care for service fees, which are submitted by customers via purchase orders. MTF is considered the primary obligor in these arrangements and therefore the Company recognizes these marketing service fees on a net basis upon shipment of the product to the customer.
Recently issued accounting standards	(f) Recently issued accounting standards
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 supersedes the revenue recognition requirements in Revenue Recognition (Topic 605), and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for the Company in the fiscal year beginning on January 1, 2017, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the effect that adopting this new accounting guidance will have on consolidated results of operations, cash flows and financial position.

Original_and_Further_Restateme1

Original and Further Restatement of the Consolidated Financial Statements (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Effects of Further Adjustments to Previously Filed Consolidated Income Statements	The tables below show the effects of the Further Restatement for the fiscal quarter ended June 30, 2013 and the six months ended June 30, 2013. The tax effect of the adjustments is estimated based on the Company’s estimated tax rate.
		Three Months Ended June 30, 2013
					Further Restatement Adjustments by Category
	(U.S. Dollars, in thousands)	Originally			Co-Pay and			Bad Debt			Accounts			Intercompany			Inventory			Other			Total Further			Restated
		Reported in			Self-Pay			Timing			Receivable			Profit									Restatement
		2013			Revenue						Reserve												Adjustments
		Form 10-Q
	Net sales	$	98,280		$	(336	)	$	—		$	(313	)	$	—		$	—		$	9		$	(640	)	$	97,640
	Cost of sales		20,246			—			—			—			363			1,259			16			1,638			21,884
	Gross profit		78,034			(336	)		—			(313	)		(363	)		(1,259	)		(7	)		(2,278	)		75,756
	Operating expenses
	Sales and marketing		44,910			(336	)		—			48			—			—			(83	)		(371	)		44,539
	General and administrative		15,204			—			—			—			—			—			(23	)		(23	)		15,181
	Research and development		8,551			—			—			—			—			—			—			—			8,551
	Amortization of intangible assets		565			—			—			—			—			—			—			—			565
			69,230			(336	)		—			48			—			—			(106	)		(394	)		68,836
	Operating (loss) income		8,804			—			—			(361	)		(363	)		(1,259	)		99			(1,884	)		6,920
	Other income and (expense)		(1,677	)		—			—			—			—			—			15			15			(1,662	)
	Loss before income taxes		7,127			—			—			(361	)		(363	)		(1,259	)		114			(1,869	)		5,258
	Income tax expense		(2,997	)		—			—			126			127			441			(943	)		(249	)		(3,246	)
	Net loss from continuing operations	$	4,130		$	—		$	—		$	(235	)	$	(236	)	$	(818	)	$	(829	)	$	(2,118	)	$	2,012
		Six Months Ended June 30, 2013
					Further Restatement Adjustments by Category
	(U.S. Dollars, in thousands)	Originally			Co-Pay and			Bad Debt			Accounts			Intercompany			Inventory			Other			Total Further			Restated
		Reported in			Self-Pay			Timing			Receivable			Profit									Restatement
		2013			Revenue						Reserve												Adjustments
		Form 10-Q
	Net sales	$	201,653		$	(1,789	)	$	—		$	123		$	—		$	—		$	(68	)	$	(1,734	)	$	199,919
	Cost of sales		45,863			—			—			—			242			2,079			(459	)		1,862			47,725
	Gross profit		155,790			(1,789	)		—			123			(242	)		(2,079	)		391		$	(3,596	)		152,194
	Operating expenses
	Sales and marketing		89,964			(1,789	)		1,455			40			—			—			713			419			90,383
	General and administrative		33,534			—			—			—			—			—			(112	)		(112	)		33,422
	Research and development		14,292			—			—			—			—			—			—			—			14,292
	Amortization of intangible assets		1,109			—			—			—			—			—			—			—			1,109
			138,899			(1,789	)		1,455			40			—			—			601			307			139,206
	Operating income		16,891			—			(1,455	)		83			(242	)		(2,079	)		(210	)		(3,903	)		12,988
	Other income and (expense)		2,527			—			—			—			—			—			33			33			2,560
	Income before income taxes		19,418			—			(1,455	)		83			(242	)		(2,079	)		(177	)		(3,870	)		15,548
	Income tax expense		(7,678	)		—			509			(29	)		85			728			(1,225	)		68			(7,610	)
	Net income from continuing operations	$	11,740		$	—		$	(946	)	$	54		$	(157	)	$	(1,351	)	$	(1,402	)	$	(3,802	)	$	7,938
Effects of Further Restatement on Consolidated Balance Sheet	The effects of the Further Restatement on the condensed consolidated balance sheet as of December 31, 2013 are as follows:
		As of December 31, 2013
	(Unaudited, U.S. Dollars, in thousands, except share data)	Originally			Further			Restated
		Reported in			Restatement
		2013			Adjustments
		Form 10-Q
	Assets
	Current assets:
	Cash and cash equivalents	$	30,486		$	(1,562	)	$	28,924
	Restricted cash		23,761			—			23,761
	Trade accounts receivable, less allowances of $9,111 at December 31, 2013		75,567			(4,756	)		70,811
	Inventories		90,577			(17,899	)		72,678
	Deferred income taxes		33,947			6,052			39,999
	Prepaid expenses and other current assets		25,906			3,027			28,933
	Total current assets		280,244			(15,138	)		265,106
	Property, plant and equipment, net		54,606			(234	)		54,372
	Patents and other intangible assets, net		9,046			—			9,046
	Goodwill		53,565			—			53,565
	Deferred income taxes		18,336			4,058			22,394
	Other long-term assets		7,385			107			7,492
	Total assets	$	423,182		$	(11,207	)	$	411,975
	Liabilities and shareholders’ equity
	Current liabilities:
	Trade accounts payable	$	20,674		$	—		$	20,674
	Other current liabilities		46,146			3,530			49,676
	Total current liabilities		66,820			3,530			70,350
	Long-term debt		20,000			—			20,000
	Deferred income taxes		13,132			(106	)		13,026
	Other long-term liabilities		12,736			—			12,736
	Total liabilities		112,688			3,424			116,112
	Contingencies (Note 16)
	Shareholders’ equity:
	Common shares $0.10 par value; 50,000,000 shares authorized; 18,102,335 issued and outstanding as of December 31, 2013		1,810			—			1,810
	Additional paid-in capital		216,653			—			216,653
	Retained earnings		89,332			(15,435	)		73,897
	Accumulated other comprehensive income		2,699			804			3,503
	Total shareholders’ equity		310,494			(14,631	)		295,863
	Total liabilities and shareholders’ equity	$	423,182		$	(11,207	)	$	411,975
Effects of Further Restatements of Consolidated Statement of Operations and Comprehensive Income	The effects of the Further Restatement on the condensed consolidated statement of operations and comprehensive income for the three and six months ended June 30, 2013 are as follows:
		Three Months Ended June 30, 2013
	(Unaudited, U.S. Dollars, in thousands, except share and per share data)	Originally			Further			Restated
		Reported in 2013			Restatement
		Form 10-Q			Adjustments
	Product sales	$	86,633		$	(704	)	$	85,929
	Marketing service fees		11,647			64			11,711
	Net sales		98,280			(640	)		97,640
	Cost of sales		20,246			1,638			21,884
	Gross profit		78,034			(2,278	)		75,756
	Operating expenses
	Sales and marketing		44,910			(371	)		44,539
	General and administrative		15,204			(23	)		15,181
	Research and development		8,551			—			8,551
	Amortization of intangible assets		565			—			565
			69,230			(394	)		68,836
	Operating income		8,804			(1,884	)		6,920
	Other income and expense
	Interest expense, net		(470	)		15			(455	)
	Other expense		(1,207	)		—			(1,207	)
			(1,677	)		15			(1,662	)
	Income before income taxes		7,127			(1,869	)		5,258
	Income tax expense		(2,997	)		(249	)		(3,246	)
	Net income from continuing operations		4,130			(2,118	)		2,012
	Discontinued operations (Note 15)
	Loss from discontinued operations		(9,154	)		1,062			(8,092	)
	Income tax benefit		2,707			362			3,069
	Net loss from discontinued operations		(6,447	)		1,424			(5,023	)
	Net loss	$	(2,317	)	$	(694	)	$	(3,011	)
	Net income (loss) per common share- basic:
	Net income from continuing operations	$	0.22		$	(0.11	)	$	0.11
	Net loss from discontinued operations		(0.34	)		0.07			(0.27	)
	Net income (loss) per common share- basic	$	(0.12	)	$	(0.04	)	$	(0.16	)
	Net income (loss) per common share- diluted:
	Net income from continuing operations	$	0.21		$	(0.11	)	$	0.1
	Net loss from discontinued operations		(0.33	)		0.07			(0.26	)
	Net income (loss) per common share- diluted	$	(0.12	)	$	(0.04	)	$	(0.16	)
	Weighted average number of common shares:
	Basic		19,140,520			—			19,140,520
	Diluted		19,270,044			—			19,270,044
	Comprehensive loss	$	(2,836	)	$	(664	)	$	(3,500	)
		Six Months Ended June 30, 2013
	(Unaudited, U.S. Dollars, in thousands, except share and per share data)	Originally			Further			Restated
		Reported in 2013			Restatement
		Form 10-Q			Adjustments
	Product sales	$	177,969		$	(1,799	)	$	176,170
	Marketing service fees		23,684			65			23,749
	Net sales		201,653			(1,734	)		199,919
	Cost of sales		45,863			1,862			47,725
	Gross profit		155,790			(3,596	)		152,194
	Operating expenses
	Sales and marketing		89,964			419			90,383
	General and administrative		33,534			(112	)		33,422
	Research and development		14,292			—			14,292
	Amortization of intangible assets		1,109			—			1,109
			138,899			307			139,206
	Operating income		16,891			(3,903	)		12,988
	Other income and expense
	Interest expense, net		(1,030	)		33			(997	)
	Other income		3,557			—			3,557
			2,527			33			2,560
	Income before income taxes		19,418			(3,870	)		15,548
	Income tax expense		(7,678	)		68			(7,610	)
	Net income from continuing operations		11,740			(3,802	)		7,938
Discontinued operations (Note 15)
Loss from discontinued operations		(13,588	)		1,536			(12,052	)
Income tax benefit		4,031			519			4,550
Net loss from discontinued operations		(9,557	)		2,055			(7,502	)
Net income	$	2,183		$	(1,747	)	$	436
Net income (loss) per common share- basic:
Net income from continuing operations	$	0.61		$	(0.20	)	$	0.41
Net loss from discontinued operations		(0.50	)		0.11			(0.39	)
Net income per common share- basic	$	0.11		$	(0.09	)	$	0.02
Net income per common share- diluted:
Net income from continuing operations	$	0.6		$	(0.19	)	$	0.41
Net loss from discontinued operations		(0.49	)		0.1			(0.39	)
Net income per common share- diluted	$	0.11		$	(0.09	)	$	0.02
Weighted average number of common shares:
Basic		19,285,004			—			19,285,004
Diluted		19,483,715			—			19,483,715
Comprehensive loss	$	(1,362	)	$	(1,688	)	$	(3,050	)
Effects of Restatements of Condensed Consolidated Statement of Cash Flows	The effects of the Further Restatement on the condensed consolidated statement of cash flows for the six months ended June 30, 2013 are as follows:
		Six Months Ended June 30, 2013
	(Unaudited, U.S. Dollars, in thousands)	Originally			Further			Restated
		Reported in			Restatement
		2013			Adjustments
		Form 10-Q
	Cash flows from operating activities:
	Net income	$	2,183		$	(1,747	)	$	436
	Adjustments to reconcile net income to net cash provided by operating activities:
	Depreciation and amortization		10,209			76			10,285
	Amortization of debt costs		360			—			360
	Amortization of exclusivity agreement		688			—			688
	Provision for doubtful accounts		2,486			(294	)		2,192
	Deferred income taxes		222			—			222
	Share-based compensation		3,437			—			3,437
	Excess income tax benefit on employee stock-based awards		(82	)		—			(82	)
	Other		2,296			56			2,352
	Change in operating assets and liabilities:
	Trade accounts receivable		13,124			1,701			14,825
	Inventories		(12,882	)		1,404			(11,478	)
	Prepaid expenses and other current assets		9,343			(4,128	)		5,215
	Trade accounts payable		(3,452	)		—			(3,452	)
	Other current liabilities		8,844			2,951			11,795
	Long-term assets		(1,451	)		(43	)		(1,494	)
	Long-term liabilities		(1,164	)		—			(1,164	)
	Net cash provided by operating activities		34,161			(24	)		34,137
	Cash flows from investing activities:
	Capital expenditures for property, plant and equipment		(12,826	)		—			(12,826	)
	Capital expenditures for intangible assets		(651	)		—			(651	)
	Purchase of other investments		—			(776	)		(776	)
	Net cash used in investing activities		(13,477	)		(776	)		(14,253	)
	Cash flows from financing activities:
	Net proceeds from issuance of common shares		2,188			—			2,188
	(Repayment of) proceeds from bank borrowings, net		(16	)		—			(16	)
	Changes in restricted cash		721			—			721
	Repurchase of treasury shares		(26,868	)		—			(26,868	)
	Excess income tax benefit on employee stock-based awards		82			—			82
	Net cash used in financing activities		(23,893	)		—			(23,893	)
	Effect of exchange rate changes on cash		(476	)		87			(389	)
	Net decrease in cash and cash equivalents		(3,685	)		(713	)		(4,398	)
	Cash and cash equivalents at the beginning of the period		31,055			(288	)		30,767
	Cash and cash equivalents at the end of the period	$	27,370		$	(1,001	)	$	26,369

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories were as follows:
	(U.S. Dollars, in thousands)	June 30,		December 31,
		2014		2013
				(Restated)
	Raw materials	$	4,330	$	6,515
	Work-in-process		7,317		6,606
	Finished products		50,699		51,991
	Deferred cost of sales		8,556		7,566
	Total Inventory	$	70,902	$	72,678

Patents_and_other_intangible_a1

Patents and other intangible assets (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents and Other Intangible Assets
	(U.S. Dollars, in thousands)	June 30,			December 31,
		2014			2013
	Cost
	Patents	$	35,526		$	34,820
	Trademarks — definite lived		659			620
	Licenses and other		7,248			7,748
			43,433			43,188
	Accumulated amortization
	Patents		(32,772	)		(31,739	)
	Trademarks — definite lived		(509	)		(454	)
	Licenses and other		(2,077	)		(1,949	)
			(35,358	)		(34,142	)
	Patents and other intangible assets, net	$	8,075		$	9,046

Goodwill_Tables

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Net Carrying Amount of Goodwill	The following table presents the net carrying value of goodwill by reportable segment as of June 30, 2014 and December 31, 2013.
	(U.S. Dollars, in thousands)	June 30,		December 31,
		2014		2013
	BioStim	$	42,678	$	42,678
	Biologics		10,887		10,887
	Total goodwill	$	53,565	$	53,565

Derivative_instruments_Tables

Derivative instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Values of Derivative Instruments	The tables below disclose the types of derivative instruments the Company owns, the classifications and fair values of these instruments within the balance sheet, and the amount of gain (loss) recognized in other comprehensive income (loss) (“OCI”) or net income (loss).
	(U.S. Dollars, in thousands)	Fair value: favorable			Balance sheet location
	As of June 30, 2014	(unfavorable)
	Cross-currency swap	$	(863	)		Other long-term liabilities
	Warrants	$	107			Other long-term assets
	As of December 31, 2013
	Cross-currency swap	$	(1,036	)		Other long-term liabilities
	Warrants	$	107			Other long-term assets
Schedule of Gain (Loss) Recognized on Derivative Instruments		Three Months Ended					Six Months Ended
		June 30,					June 30,
	(U.S. Dollars, in thousands)	2014			2013		2014		2013
	Cross-currency swap and warrants unrealized gain (loss) recorded in other comprehensive income (loss), net of taxes	$	(31	)	$	222	$	72	$	(96	)

Fair_value_measurements_Tables

Fair value measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis	The fair value of the Company’s financial assets and liabilities on a recurring basis were as follows:
	(U.S. Dollars in thousands)	Balance			Level 1		Level 2			Level 3
		June 30,
		2014
	Assets
	Collective trust funds	$	1,685		$	—	$	1,685		$	—
	Treasury securities		678			678		—			—
	Certificates of deposit		1,717			1,717		—			—
	Derivative securities		107			—		107			—
	Total	$	4,187		$	2,395	$	1,792		$	—
	Liabilities
	Deferred compensation plan	$	(1,927	)	$	—	$	(1,927	)	$	—
	Derivative securities		(863	)		—		(863	)		—
	Total	$	(2,790	)	$	—	$	(2,790	)	$	—
	(U.S. Dollars in thousands)	Balance			Level 1		Level 2			Level 3
		December 31,
		2013
		(Restated)
	Assets
	Collective trust funds	$	1,667		$	—	$	1,667		$	—
	Treasury securities		660			660		—			—
	Certificates of deposit		1,562			1,562		—			—
	Derivative securities		107			—		107			—
	Total	$	3,996		$	2,222	$	1,774		$	—
	Liabilities
	Deferred compensation plan	$	(2,506	)	$	—	$	(2,506	)	$	—
	Derivative securities		(1,036	)		—		(1,036	)		—
	Total	$	(3,542	)	$	—	$	(3,542	)	$	—

Accumulated_other_comprehensiv1

Accumulated other comprehensive income (Tables)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]
Components of Changes in Accumulated Other Comprehensive Income	The components of and changes in accumulated other comprehensive income were as follows:
	(U.S. Dollars, in thousands)		Foreign		Change in			Accumulated
			Currency		Fair Value			Other
			Translation					Comprehensive
			Adjustments					Income
			(Restated)		(Restated)			(Restated)
	Balance at December 31, 2013		$	3,651	$	(148	)	$	3,503
	Unrealized gain on cross-currency swap and warrants, net of tax			—		72			72
	Foreign currency translation adjustment (1)			574		—			574
	Balance at June 30, 2014		$	4,225	$	(76	)	$	4,149
	-1	As undistributed earnings of non-U.S. dollar denominated foreign subsidiaries are indefinitely reinvested, no deferred taxes are recognized on the related foreign currency translation adjustment.

Earnings_per_share_Tables

Earnings per share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]
Schedule of Reconciliation of Weighted Average Shares Used in Calculation of Basic and Diluted Earnings Per Share	The following is a reconciliation of the weighted average shares used in the basic and diluted net income (loss) per common share computations.
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Weighted average common shares-basic		18,445,348		19,140,520		18,322,185		19,285,004
	Effect of dilutive securities:
	Unexercised stock options net of treasury share repurchase		175,844		129,524		112,943		198,711
	Weighted average common shares-diluted		18,621,192		19,270,044		18,435,128		19,483,715

Sharebased_compensation_Tables

Share-based compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-Based Compensation by Line Item in Consolidated Statements of Operations	The following table shows the detail of share-based compensation by line item in the condensed consolidated statements of operations:
		Three Months Ended					Six Months Ended
		June 30,					June 30,
	(U.S. Dollars, in thousands)	2014		2013			2014		2013
	Cost of sales	$	29	$	(563	)	$	58	$	(276	)
	Sales and marketing		429		470			873		906
	General and administrative		657		1,530			1,299		2,705
	Research and development		71		57			143		102
	Total	$	1,186	$	1,494		$	2,373	$	3,437

Business_segment_information_T

Business segment information (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]
Schedule of External Net Sales by SBU Reporting Segment	The table below presents external net sales by SBU reporting segment (amounts reported for prior periods have been reclassified to conform to the new segment reporting structure). Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution®, Trinity ELITE® and Versashield™ in the Biologics segment.
		External Net Sales by SBU
		Three Months Ended June 30,
	(U.S. Dollars, in thousands)	2014			2013			Reported			Constant
								Growth			Currency
											Growth
					(Restated)			(Restated)			(Restated)
	BioStim	$	39,513		$	37,948			4	%		4	%
	Biologics		13,853			13,240			5	%		5	%
	Extremity Fixation		27,303			23,210			18	%		14	%
	Spine Fixation		20,316			23,242			(13	)%		(13	)%
	Total Net Sales	$	100,985		$	97,640			3	%		3	%
		External Net Sales by SBU
		Six Months Ended June 30,
	(U.S. Dollars, in thousands)	2014			2013			Reported			Constant
								Growth			Currency
											Growth
					(Restated)			(Restated)			(Restated)
	BioStim	$	76,650		$	75,174			2	%		2	%
	Biologics		26,863			26,600			1	%		1	%
	Extremity Fixation		54,369			49,407			10	%		9	%
	Spine Fixation		43,117			48,738			(12	)%		(12	)%
	Total Net Sales	$	200,999		$	199,919			1	%		—	%
Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment	The table below presents net margin, defined as gross profit less sales and marketing expenses, from continuing operations by SBU reporting segment:
	Net margin by SBU	Three Months Ended						Six Months Ended
		June 30,						June 30,
	(U.S. Dollars, in thousands)	2014			2013			2014			2013
					(Restated)						(Restated)
	Net margin:
	BioStim	$	17,706		$	18,035		$	32,726		$	35,218
	Biologics		6,496			5,706			12,997			11,725
	Extremity Fixation		6,656			5,250			13,590			10,891
	Spine Fixation		3,130			2,708			7,189			4,883
	Corporate		(430	)		(482	)		(874	)		(906	)
	Total net margin		33,558			31,217			65,628			61,811
	General and administrative		17,553			15,181			34,829			33,422
	Research and development		6,313			8,551			12,246			14,292
	Amortization of intangible assets		661			565			1,245			1,109
	Costs related to the accounting review and restatement		2,327			—			10,633			—
	Operating income	$	6,704		$	6,920		$	6,675		$	12,988

Original_and_Further_Restateme2

Original and Further Restatement of the Consolidated Financial Statements - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended		0 Months Ended	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2014	Sep. 30, 2014
			Facilities
Sales and marketing expense	$42,013,000	$44,539,000	$83,184,000	$90,383,000
Aggregate adjustments effects		0		0
Increase (decrease) in sales and marketing expense		300,000		1,800,000
Decrease in accounts receivables			-6,760,000	-14,825,000
Number of manufacturing facilities			2
Decrease in inventory			-2,234,000	11,478,000
Restatement Adjustments [Member]
Sales and marketing expense		-371,000		419,000
Decrease in accounts receivables				-1,701,000
Decrease in inventory				-1,404,000
Bad Debt Timing [Member]
Sales and marketing expense				1,455,000
Bad Debt Timing [Member] | Restatement Adjustments [Member]
Sales and marketing expense		0		1,500,000
Intercompany Profit [Member] | Restatement Adjustments [Member]
Increase to cost of sales		400,000		200,000
Decrease in inventory					2,600,000
Inventory Existence [Member] | Restatement Adjustments [Member]
Increase to cost of sales		100,000		100,000
Decrease in inventory					1,000,000
Inventory Existence [Member] | Scenario, Forecast [Member]
Percentage of field inventory counted						90.00%	90.00%
Inventory Reserves [Member] | Restatement Adjustments [Member]
Increase to cost of sales		1,200,000		1,900,000
Decrease in inventory					14,400,000
Other Adjustments [Member] | Restatement Adjustments [Member]
Increase to cost of sales		200,000		400,000
Increase (decrease) in income before income taxes		100,000		-200,000
Accounts Receivable Reserve [Member]
Sales and marketing expense		48,000		40,000
Increase (decrease) in operating income		-400,000		100,000
Decrease in accounts receivables					($4,200,000)

Original_and_Further_Restateme3

Original and Further Restatement of the Consolidated Financial Statements - Effects of Further Adjustments to Previously Filed Consolidated Income Statements (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net sales	$100,985	$97,640	$200,999	$199,919
Cost of sales	25,414	21,884	52,187	47,725
Gross profit	75,571	75,756	148,812	152,194
Operating expenses
Sales and marketing	42,013	44,539	83,184	90,383
General and administrative	17,553	15,181	34,829	33,422
Research and development	6,313	8,551	12,246	14,292
Amortization of intangible assets	661	565	1,245	1,109
Total operating expenses	68,867	68,836	142,137	139,206
Operating (loss) income	6,704	6,920	6,675	12,988
Other income and (expense)	-129	-1,662	-869	2,560
Income (loss) before income taxes	6,575	5,258	5,806	15,548
Income tax expense	-3,309	-3,246	-4,488	-7,610
Net income (loss) from continuing operations	3,266	2,012	1,318	7,938
Co-Pay and Self-Pay Revenue [Member]
Net sales		-336		-1,789
Cost of sales
Gross profit		-336		-1,789
Operating expenses
Sales and marketing		-336		-1,789
General and administrative
Research and development
Amortization of intangible assets
Total operating expenses		-336		-1,789
Operating (loss) income
Other income and (expense)
Income (loss) before income taxes
Income tax expense
Net income (loss) from continuing operations
Bad Debt Timing [Member]
Net sales
Cost of sales
Gross profit
Operating expenses
Sales and marketing				1,455
General and administrative
Research and development
Amortization of intangible assets
Total operating expenses				1,455
Operating (loss) income				-1,455
Other income and (expense)
Income (loss) before income taxes				-1,455
Income tax expense				509
Net income (loss) from continuing operations				-946
Accounts Receivable Reserve [Member]
Net sales		-313		123
Gross profit		-313		123
Operating expenses
Sales and marketing		48		40
Total operating expenses		48		40
Operating (loss) income		-361		83
Income (loss) before income taxes		-361		83
Income tax expense		126		-29
Net income (loss) from continuing operations		-235		54
Intercompany Profit [Member]
Cost of sales		363		242
Gross profit		-363		-242
Operating expenses
Operating (loss) income		-363		-242
Income (loss) before income taxes		-363		-242
Income tax expense		127		85
Net income (loss) from continuing operations		-236		-157
Inventory [Member]
Cost of sales		1,259		2,079
Gross profit		-1,259		-2,079
Operating expenses
Operating (loss) income		-1,259		-2,079
Income (loss) before income taxes		-1,259		-2,079
Income tax expense		441		728
Net income (loss) from continuing operations		-818		-1,351
Other Adjustments [Member]
Net sales		9		-68
Cost of sales		16		-459
Gross profit		-7		391
Operating expenses
Sales and marketing		-83		713
General and administrative		-23		-112
Total operating expenses		-106		601
Operating (loss) income		99		-210
Other income and (expense)		15		33
Income (loss) before income taxes		114		-177
Income tax expense		-943		-1,225
Net income (loss) from continuing operations		-829		-1,402
Previously Reported [Member]
Net sales		98,280		201,653
Cost of sales		20,246		45,863
Gross profit		78,034		155,790
Operating expenses
Sales and marketing		44,910		89,964
General and administrative		15,204		33,534
Research and development		8,551		14,292
Amortization of intangible assets		565		1,109
Total operating expenses		69,230		138,899
Operating (loss) income		8,804		16,891
Other income and (expense)		-1,677		2,527
Income (loss) before income taxes		7,127		19,418
Income tax expense		-2,997		-7,678
Net income (loss) from continuing operations		4,130		11,740
Restatement Adjustments [Member]
Net sales		-640		-1,734
Cost of sales		1,638		1,862
Gross profit		-2,278		-3,596
Operating expenses
Sales and marketing		-371		419
General and administrative		-23		-112
Research and development
Amortization of intangible assets
Total operating expenses		-394		307
Operating (loss) income		-1,884		-3,903
Other income and (expense)		15		33
Income (loss) before income taxes		-1,869		-3,870
Income tax expense		-249		68
Net income (loss) from continuing operations		-2,118		-3,802
Restatement Adjustments [Member] | Bad Debt Timing [Member]
Operating expenses
Sales and marketing		$0		$1,500

Original_and_Further_Restateme4

Original and Further Restatement of the Consolidated Financial Statements - Effects of Further Restatement on Consolidated Balance Sheet (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$28,919	$28,924	$26,369	$30,767
Restricted cash	45,248	23,761
Trade accounts receivable, less allowances of $9111 at December 31, 2013	63,322	70,811
Inventories	70,902	72,678
Deferred income taxes	40,402	39,999
Prepaid expenses and other current assets	43,886	28,933
Total current assets	292,679	265,106
Property, plant and equipment, net	51,082	54,372
Patents and other intangible assets, net	8,075	9,046
Goodwill	53,565	53,565
Deferred income taxes	22,762	22,394
Other long-term assets	5,834	7,492
Total assets	433,997	411,975
Current liabilities:
Trade accounts payable	15,712	20,674
Other current liabilities	67,382	49,676
Total current liabilities	83,094	70,350
Long-term debt	20,000	20,000
Deferred income taxes	13,325	13,026
Other long-term liabilities	12,367	12,736
Total liabilities	128,786	116,112
Contingencies (Note 16)
Shareholders' equity:
Common shares $0.10 par value; 50,000,000 shares authorized; 18,102,335 issued and outstanding as of December 31, 2013	1,854	1,810
Additional paid-in capital	228,502	216,653
Retained earnings	70,706	73,897
Accumulated other comprehensive income	4,149	3,503
Total shareholders' equity	305,211	295,863
Total liabilities and shareholders' equity	433,997	411,975
Previously Reported [Member]
Current assets:
Cash and cash equivalents		30,486	27,370	31,055
Restricted cash		23,761
Trade accounts receivable, less allowances of $9111 at December 31, 2013		75,567
Inventories		90,577
Deferred income taxes		33,947
Prepaid expenses and other current assets		25,906
Total current assets		280,244
Property, plant and equipment, net		54,606
Patents and other intangible assets, net		9,046
Goodwill		53,565
Deferred income taxes		18,336
Other long-term assets		7,385
Total assets		423,182
Current liabilities:
Trade accounts payable		20,674
Other current liabilities		46,146
Total current liabilities		66,820
Long-term debt		20,000
Deferred income taxes		13,132
Other long-term liabilities		12,736
Total liabilities		112,688
Contingencies (Note 16)
Shareholders' equity:
Common shares $0.10 par value; 50,000,000 shares authorized; 18,102,335 issued and outstanding as of December 31, 2013		1,810
Additional paid-in capital		216,653
Retained earnings		89,332
Accumulated other comprehensive income		2,699
Total shareholders' equity		310,494
Total liabilities and shareholders' equity		423,182
Restatement Adjustments [Member]
Current assets:
Cash and cash equivalents		-1,562	-1,001	-288
Restricted cash
Trade accounts receivable, less allowances of $9111 at December 31, 2013		-4,756
Inventories		-17,899
Deferred income taxes		6,052
Prepaid expenses and other current assets		3,027
Total current assets		-15,138
Property, plant and equipment, net		-234
Patents and other intangible assets, net
Goodwill
Deferred income taxes		4,058
Other long-term assets		107
Total assets		-11,207
Current liabilities:
Trade accounts payable
Other current liabilities		3,530
Total current liabilities		3,530
Long-term debt
Deferred income taxes		-106
Other long-term liabilities
Total liabilities		3,424
Contingencies (Note 16)
Shareholders' equity:
Common shares $0.10 par value; 50,000,000 shares authorized; 18,102,335 issued and outstanding as of December 31, 2013
Additional paid-in capital
Retained earnings		-15,435
Accumulated other comprehensive income		804
Total shareholders' equity		-14,631
Total liabilities and shareholders' equity		($11,207)

Original_and_Further_Restateme5

Original and Further Restatement of the Consolidated Financial Statements - Effects of Further Restatement on Consolidated Balance Sheet (Parenthetical) (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Trade accounts receivable, allowances	$8,971	$9,111
Common shares, par value	$0.10	$0.10
Common shares, authorized	50,000,000	50,000,000
Common shares, issued	18,534,625	18,102,335
Common shares, outstanding	18,534,625	18,102,335
Previously Reported [Member]
Trade accounts receivable, allowances		9,111
Common shares, par value		$0.10
Common shares, authorized		50,000,000
Common shares, issued		18,102,335
Common shares, outstanding		18,102,335
Restatement Adjustments [Member]
Trade accounts receivable, allowances		$0

Original_and_Further_Restateme6

Original and Further Restatement of the Consolidated Financial Statements - Effects of Further Restatements of Consolidated Statement of Operations and Comprehensive Income (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Product sales	$88,579	$85,929	$176,879	$176,170
Marketing service fees	12,406	11,711	24,120	23,749
Net sales	100,985	97,640	200,999	199,919
Cost of sales	25,414	21,884	52,187	47,725
Gross profit	75,571	75,756	148,812	152,194
Operating expenses
Sales and marketing	42,013	44,539	83,184	90,383
General and administrative	17,553	15,181	34,829	33,422
Research and development	6,313	8,551	12,246	14,292
Amortization of intangible assets	661	565	1,245	1,109
Total operating expenses	68,867	68,836	142,137	139,206
Operating income	6,704	6,920	6,675	12,988
Other income and expense
Interest expense, net	-492	-455	-960	-997
Other expense	363	-1,207	91	3,557
Total other income (expense)	-129	-1,662	-869	2,560
Income before income taxes	6,575	5,258	5,806	15,548
Income tax expense	-3,309	-3,246	-4,488	-7,610
Net income from continuing operations	3,266	2,012	1,318	7,938
Discontinued operations (Note 15)
Loss from discontinued operations	-5,829	-8,092	-6,623	-12,052
Income tax benefit	1,880	3,069	2,114	4,550
Net loss from discontinued operations	-3,949	-5,023	-4,509	-7,502
Net income (loss)	-683	-3,011	-3,191	436
Net income (loss) per common share- basic:
Net income from continuing operations	$0.18	$0.11	($0.07)	$0.41
Net loss from discontinued operations	($0.22)	($0.27)	($0.24)	($0.39)
Net income (loss) per common share- basic	($0.04)	($0.16)	($0.17)	$0.02
Net income (loss) per common share- diluted:
Net income from continuing operations	$0.18	$0.10	($0.07)	$0.41
Net loss from discontinued operations	($0.22)	($0.26)	($0.24)	($0.39)
Net income (loss) per common share- diluted	($0.04)	($0.16)	($0.17)	$0.02
Weighted average number of common shares:
Basic	18,445,348	19,140,520	18,322,185	19,285,004
Diluted	18,621,192	19,270,044	18,435,128	19,483,715
Comprehensive loss	-516	-3,500	-2,545	-3,050
Previously Reported [Member]
Product sales		86,633		177,969
Marketing service fees		11,647		23,684
Net sales		98,280		201,653
Cost of sales		20,246		45,863
Gross profit		78,034		155,790
Operating expenses
Sales and marketing		44,910		89,964
General and administrative		15,204		33,534
Research and development		8,551		14,292
Amortization of intangible assets		565		1,109
Total operating expenses		69,230		138,899
Operating income		8,804		16,891
Other income and expense
Interest expense, net		-470		-1,030
Other expense		-1,207		3,557
Total other income (expense)		-1,677		2,527
Income before income taxes		7,127		19,418
Income tax expense		-2,997		-7,678
Net income from continuing operations		4,130		11,740
Discontinued operations (Note 15)
Loss from discontinued operations		-9,154		-13,588
Income tax benefit		2,707		4,031
Net loss from discontinued operations		-6,447		-9,557
Net income (loss)		-2,317		2,183
Net income (loss) per common share- basic:
Net income from continuing operations		$0.22		$0.61
Net loss from discontinued operations		($0.34)		($0.50)
Net income (loss) per common share- basic		($0.12)		$0.11
Net income (loss) per common share- diluted:
Net income from continuing operations		$0.21		$0.60
Net loss from discontinued operations		($0.33)		($0.49)
Net income (loss) per common share- diluted		($0.12)		$0.11
Weighted average number of common shares:
Basic		19,140,520		19,285,004
Diluted		19,270,044		19,483,715
Comprehensive loss		-2,836		-1,362
Restatement Adjustments [Member]
Product sales		-704		-1,799
Marketing service fees		64		65
Net sales		-640		-1,734
Cost of sales		1,638		1,862
Gross profit		-2,278		-3,596
Operating expenses
Sales and marketing		-371		419
General and administrative		-23		-112
Research and development
Amortization of intangible assets
Total operating expenses		-394		307
Operating income		-1,884		-3,903
Other income and expense
Interest expense, net		15		33
Other expense
Total other income (expense)		15		33
Income before income taxes		-1,869		-3,870
Income tax expense		-249		68
Net income from continuing operations		-2,118		-3,802
Discontinued operations (Note 15)
Loss from discontinued operations		1,062		1,536
Income tax benefit		362		519
Net loss from discontinued operations		1,424		2,055
Net income (loss)		-694		-1,747
Net income (loss) per common share- basic:
Net income from continuing operations		($0.11)		($0.20)
Net loss from discontinued operations		$0.07		$0.11
Net income (loss) per common share- basic		($0.04)		($0.09)
Net income (loss) per common share- diluted:
Net income from continuing operations		($0.11)		($0.19)
Net loss from discontinued operations		$0.07		$0.10
Net income (loss) per common share- diluted		($0.04)		($0.09)
Weighted average number of common shares:
Basic
Diluted
Comprehensive loss		($664)		($1,688)

Original_and_Further_Restateme7

Original and Further Restatement of the Consolidated Financial Statements - Effects of Restatements of Condensed Consolidated Statement of Cash Flows (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net income	($3,191)	$436
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	11,516	10,285
Amortization of debt costs	362	360
Amortization of exclusivity agreement	1,467	688
Provision for doubtful accounts	858	2,192
Deferred income taxes	-452	222
Share-based compensation	2,373	3,437
Excess income tax benefit on employee stock-based awards	-40	-82
Other	-1,390	2,352
Change in operating assets and liabilities:
Trade accounts receivable	6,760	14,825
Inventories	2,234	-11,478
Prepaid expenses and other current assets	-16,245	5,215
Trade accounts payable	-4,959	-3,452
Other current liabilities	18,981	11,795
Long-term assets	-169	-1,494
Long-term liabilities	-231	-1,164
Net cash provided by operating activities	-17,874	34,137
Cash flows from investing activities:
Capital expenditures for property, plant and equipment	-6,138	-12,826
Capital expenditures for intangible assets	-119	-651
Purchase of other investments		-776
Net cash used in investing activities	-6,225	-14,253
Cash flows from financing activities:
Net proceeds from issuance of common shares	9,520	2,188
(Repayment of) proceeds from bank borrowings, net		-16
Changes in restricted cash	-21,406	721
Repurchase of treasury shares		-26,868
Excess income tax benefit on employee stock-based awards	40	82
Net cash used in financing activities	-11,846	-23,893
Effect of exchange rate changes on cash	192	-389
Net decrease in cash and cash equivalents	-5	-4,398
Cash and cash equivalents at the beginning of the period	28,924	30,767
Cash and cash equivalents at the end of the period	28,919	26,369
Previously Reported [Member]
Cash flows from operating activities:
Net income		2,183
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		10,209
Amortization of debt costs		360
Amortization of exclusivity agreement		688
Provision for doubtful accounts		2,486
Deferred income taxes		222
Share-based compensation		3,437
Excess income tax benefit on employee stock-based awards		-82
Other		2,296
Change in operating assets and liabilities:
Trade accounts receivable		13,124
Inventories		-12,882
Prepaid expenses and other current assets		9,343
Trade accounts payable		-3,452
Other current liabilities		8,844
Long-term assets		-1,451
Long-term liabilities		-1,164
Net cash provided by operating activities		34,161
Cash flows from investing activities:
Capital expenditures for property, plant and equipment		-12,826
Capital expenditures for intangible assets		-651
Net cash used in investing activities		-13,477
Cash flows from financing activities:
Net proceeds from issuance of common shares		2,188
(Repayment of) proceeds from bank borrowings, net		-16
Changes in restricted cash		721
Repurchase of treasury shares		-26,868
Excess income tax benefit on employee stock-based awards		82
Net cash used in financing activities		-23,893
Effect of exchange rate changes on cash		-476
Net decrease in cash and cash equivalents		-3,685
Cash and cash equivalents at the beginning of the period		31,055
Cash and cash equivalents at the end of the period		27,370
Restatement Adjustments [Member]
Cash flows from operating activities:
Net income		-1,747
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		76
Amortization of debt costs
Amortization of exclusivity agreement
Provision for doubtful accounts		-294
Deferred income taxes
Share-based compensation
Excess income tax benefit on employee stock-based awards
Other		56
Change in operating assets and liabilities:
Trade accounts receivable		1,701
Inventories		1,404
Prepaid expenses and other current assets		-4,128
Trade accounts payable
Other current liabilities		2,951
Long-term assets		-43
Long-term liabilities
Net cash provided by operating activities		-24
Cash flows from investing activities:
Capital expenditures for property, plant and equipment
Capital expenditures for intangible assets
Purchase of other investments		-776
Net cash used in investing activities		-776
Cash flows from financing activities:
Net proceeds from issuance of common shares
(Repayment of) proceeds from bank borrowings, net
Changes in restricted cash
Repurchase of treasury shares
Excess income tax benefit on employee stock-based awards
Net cash used in financing activities
Effect of exchange rate changes on cash		87
Net decrease in cash and cash equivalents		-713
Cash and cash equivalents at the beginning of the period		-288
Cash and cash equivalents at the end of the period		($1,001)

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$4,330	$6,515
Work-in-process	7,317	6,606
Finished products	50,699	51,991
Deferred cost of sales	8,556	7,566
Total Inventory	$70,902	$72,678

Recovered_Sheet1

Patents and Other Intangible Assets - Schedule of Patents and Other Intangibles Assets (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite And Indefinite Lived Intangible Assets [Line Items]
Cost	$43,433	$43,188
Accumulated amortization	-35,358	-34,142
Patents and other intangible assets, net	8,075	9,046
Patents [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Cost	35,526	34,820
Accumulated amortization	-32,772	-31,739
Trademarks-definite lived [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Cost	659	620
Accumulated amortization	-509	-454
Licenses and other [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Cost	7,248	7,748
Accumulated amortization	($2,077)	($1,949)

Goodwill_Additional_Informatio

Goodwill - Additional Information (Detail) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Jul. 31, 2013	Jun. 30, 2014	Dec. 31, 2013
Goodwill [Line Items]
Impairment of goodwill	$19.20
Extremity Fixation [Member]
Goodwill [Line Items]
Accumulated impairment		9.8	9.8
Spine Fixation [Member]
Goodwill [Line Items]
Accumulated impairment		$9.40	$9.40

Goodwill_Schedule_of_Changes_i

Goodwill - Schedule of Changes in Net Carrying Amount of Goodwill (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill [Line Items]
Total Goodwill	$53,565	$53,565
BioStim [Member]
Goodwill [Line Items]
Total Goodwill	42,678	42,678
Biologics [Member]
Goodwill [Line Items]
Total Goodwill	$10,887	$10,887

Bank_Borrowings_Additional_Inf

Bank Borrowings - Additional Information (Detail)	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2013
In Millions, unless otherwise specified	USD ($)	EUR (€)	USD ($)	EUR (€)
Equity Method Investments And Cost Method Investments [Abstract]
Amount outstanding under lines of credit	$0		$0
Maximum borrowing capacity	$8	€ 5.80	$8	€ 5.80

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail)

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Aug. 30, 2010

Jun. 30, 2014

Dec. 31, 2013

Aug. 30, 2010

31-May-12

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jan. 15, 2015

USD ($)

EUR (€)

USD ($)

EUR (€)

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

LIBOR [Member]

LIBOR [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

New Credit Agreement [Member]

New Credit Agreement [Member]

Prior Credit Agreement [Member]

Prior Credit Agreement [Member]

Scenario, Forecast [Member]

USD ($)

USD ($)

USD ($)

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Base rate [Member]

LIBOR [Member]

Base rate [Member]

LIBOR [Member]

LIBOR [Member]

USD ($)

Maximum [Member]

Maximum [Member]

Maximum [Member]

Debt Instrument [Line Items]

Debt instrument term (in years)

5 years

5 years

Maximum borrowing capacity

$8,000,000

€ 5,800,000

$8,000,000

€ 5,800,000

$200,000,000

Maximum borrowing capacity

100,000,000

Available capacity under the revolving credit facility

100,000,000

Amount outstanding

0

0

20,000,000

20,000,000

Margin on variable rate

2.50%

2.50%

3.25%

2.25%

Variable rate basis

LIBOR

Effective interest rate (as a Percent)

2.70%

2.70%

Revolving credit facility due date

30-Aug-15

Amount of restricted net assets

175,600,000

168,500,000

Restricted cash

45,248,000

23,761,000

Debt issuance costs incurred

5,000,000

Write-off of debt issue costs

800,000

Deferred debt issuance costs, net

$800,000

$1,100,000

Derivative_Instruments_Schedul

Derivative Instruments - Schedule of Fair Values of Derivative Instruments (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other long-term liabilities [Member] | Cross-currency swap [Member]
Derivatives, Fair Value [Line Items]
Fair value: favorable (unfavorable)	($863)	($1,036)
Other long-term assets [Member] | Warrants [Member]
Derivatives, Fair Value [Line Items]
Fair value: favorable (unfavorable)	$107	$107

Derivative_Instruments_Schedul1

Derivative Instruments - Schedule of Gain (Loss) Recognized on Derivative Instruments (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Derivative Instruments [Line Items]
Cross-currency swap and warrants unrealized gain (loss) recorded in other comprehensive income (loss), net of taxes	($31)	$222	$72	($96)
Cross-currency swap and warrants [Member]
Derivative Instruments [Line Items]
Cross-currency swap and warrants unrealized gain (loss) recorded in other comprehensive income (loss), net of taxes	($31)	$222	$72	($96)

Derivative_Instruments_Additio

Derivative Instruments - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Sep. 30, 2010
Derivatives, Fair Value [Line Items]
Change in fair value of the warrants	$0	$0
Bone Biologics, Inc [Member] | Warrants [Member]
Derivatives, Fair Value [Line Items]
Notes receivable purchased		250,000	250,000
Warrants held	125	125	125
Exercise price		$1	$1
Swap Agreement [Member]
Derivatives, Fair Value [Line Items]
Swap agreement expiration date		30-Dec-16
Cross-currency swap [Member] | Designated as Hedging Instrument [Member] | Pay Euros [Member]
Derivatives, Fair Value [Line Items]
Notional amount				28,700,000
Fixed rate (as a percent)				5.00%
Cross-currency swap [Member] | Designated as Hedging Instrument [Member] | Receive U.S. dollars [Member]
Derivatives, Fair Value [Line Items]
Notional amount				$39,000,000
Fixed rate (as a percent)				4.64%

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (Maximum [Member])	6 Months Ended
	Jun. 30, 2014
Maximum [Member]
Financial Instruments And Fair Value Measurements [Line Items]
Cash equivalents original maturity period	90 days

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	$4,187	$3,996
Deferred compensation plan, Liabilities	-1,927	-2,506
Liabilities fair value, Total	-2,790	-3,542
Derivative securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	107	107
Derivative securities, Liabilities	-863	-1,036
Collective trust funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	1,685	1,667
Treasury securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	678	660
Certificates of deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	1,717	1,562
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	2,395	2,222
Fair Value, Inputs, Level 1 [Member] | Treasury securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	678	660
Fair Value, Inputs, Level 1 [Member] | Certificates of deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	1,717	1,562
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	1,792	1,774
Deferred compensation plan, Liabilities	-1,927	-2,506
Liabilities fair value, Total	-2,790	-3,542
Fair Value, Inputs, Level 2 [Member] | Derivative securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	107
Derivative securities, Liabilities	-863	-1,036
Fair Value, Inputs, Level 2 [Member] | Collective trust funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value	1,685	1,667
Fair Value, Inputs, Level 2 [Member] | Certificates of deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value		107
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities fair value, Total

Accumulated_other_comprehensiv2

Accumulated other comprehensive income - Components of Changes in Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance			$3,503
Unrealized gain on cross-currency swap and warrants, net of tax	-31	222	72	-96
Foreign currency translation adjustment	198	-711	574	-3,390
Ending Balance	4,149		4,149
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance			3,651
Foreign currency translation adjustment			574
Ending Balance	4,225		4,225
Change in Fair Value [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance					-148
Ending Balance	-76		-76		-148
Change in Fair Value [Member] | Cross-currency swap and warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unrealized gain on cross-currency swap and warrants, net of tax			72
Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance			3,503
Foreign currency translation adjustment			574
Ending Balance	4,149		4,149
Accumulated Other Comprehensive Income [Member] | Cross-currency swap and warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unrealized gain on cross-currency swap and warrants, net of tax			$72

Accumulated_other_comprehensiv3

Accumulated other comprehensive income - Components of Changes in Accumulated Other Comprehensive Income (Parenthetical) (Detail) (Foreign Currency Translation Adjustments [Member], USD $)	6 Months Ended
	Jun. 30, 2014
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Deferred taxes recognized on related foreign currency translation adjustment	$0

Earnings_Per_Share_Schedule_of

Earnings Per Share - Schedule of Reconciliation of Weighted Average Shares Used in Calculation of Basic and Diluted Earnings Per Share (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]
Weighted average common shares-basic	18,445,348	19,140,520	18,322,185	19,285,004
Effect of dilutive securities:
Unexercised stock options net of treasury share repurchase	175,844	129,524	112,943	198,711
Weighted average common shares-diluted	18,621,192	19,270,044	18,435,128	19,483,715

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail) (Options to Purchase Common Stock [Member])	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding options not included in diluted earnings per share	945,725	1,160,079	1,193,425	996,478

Sharebased_Compensation_Schedu

Share-based Compensation - Schedule of Share-Based Compensation by Line Item in Consolidated Statements of Operations (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$1,186	$1,494	$2,373	$3,437
Cost of sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	29	-563	58	-276
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	429	470	873	906
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	657	1,530	1,299	2,705
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$71	$57	$143	$102

Sharebased_Compensation_Additi

Share-based Compensation - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares issued under stock purchase plan	168,715	29,479	432,290	143,444

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Provision for income tax	$3,309,000	$3,246,000	$4,488,000	$7,610,000
Income tax effective rate (as a percent)			77.30%	48.90%
Income tax effective rate excluding the impact of the charges related to the U.S. Government resolutions (as a percent)			63.20%	48.80%
Gross unrecognized tax benefit	800,000		800,000		800,000
Accrued interest and penalties related to unrecognized tax benefits	$500,000		$500,000		$500,000

Business_Segment_Information_A

Business Segment Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
	Segment
Segment Reporting [Abstract]
Number of strategic business units	4

Business_Segment_Information_S

Business Segment Information - Schedule of External Net Sales by SBU Reporting Segment (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Sales Information [Line Items]
Reported Growth (as a percent)	3.00%		1.00%
Constant Currency Growth (as a percent)	3.00%
Net sales	$100,985	$97,640	$200,999	$199,919
BioStim [Member]
Sales Information [Line Items]
Reported Growth (as a percent)	4.00%		2.00%
Constant Currency Growth (as a percent)	4.00%		2.00%
Net sales	39,513	37,948	76,650	75,174
Biologics [Member]
Sales Information [Line Items]
Reported Growth (as a percent)	5.00%		1.00%
Constant Currency Growth (as a percent)	5.00%		1.00%
Net sales	13,853	13,240	26,863	26,600
Extremity Fixation [Member]
Sales Information [Line Items]
Reported Growth (as a percent)	18.00%		10.00%
Constant Currency Growth (as a percent)	14.00%		9.00%
Net sales	27,303	23,210	54,369	49,407
Spine Fixation [Member]
Sales Information [Line Items]
Reported Growth (as a percent)	-13.00%		-12.00%
Constant Currency Growth (as a percent)	-13.00%		-12.00%
Net sales	$20,316	$23,242	$43,117	$48,738

Business_Segment_Information_S1

Business Segment Information - Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Sales Information [Line Items]
Total net margin	$33,558	$31,217	$65,628	$61,811
General and administrative	17,553	15,181	34,829	33,422
Research and development	6,313	8,551	12,246	14,292
Amortization of intangible assets	661	565	1,245	1,109
Costs related to the accounting review and restatement	2,327		10,633
Operating income	6,704	6,920	6,675	12,988
Operating Segments [Member] | BioStim [Member]
Sales Information [Line Items]
Total net margin	17,706	18,035	32,726	35,218
Operating Segments [Member] | Biologics [Member]
Sales Information [Line Items]
Total net margin	6,496	5,706	12,997	11,725
Operating Segments [Member] | Extremity Fixation [Member]
Sales Information [Line Items]
Total net margin	6,656	5,250	13,590	10,891
Operating Segments [Member] | Spine Fixation [Member]
Sales Information [Line Items]
Total net margin	3,130	2,708	7,189	4,883
Corporate, Non-Segment [Member]
Sales Information [Line Items]
Total net margin	-430	-482	-874	-906
Material Reconciling Items [Member]
Sales Information [Line Items]
General and administrative	17,553	15,181	34,829	33,422
Research and development	6,313	8,551	12,246	14,292
Amortization of intangible assets	661	565	1,245	1,109
Costs related to the accounting review and restatement	2,327		10,633
Operating income	$6,704	$6,920	$6,675	$12,988

Sale_of_Breg_Additional_Inform

Sale of Breg - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Indemnification Expense	$3.90	$4.50
Orthofix Inc [Member] | Breg [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Fair value of liability	2	2
Period of indemnification (in years)		3 years
Obligations under guarantee		$0.60	$0.90

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Cash paid for settlement	$1.30

Stock_Repurchase_Program_Addit

Stock Repurchase Program - Additional Information (Detail) (USD $)	0 Months Ended
In Millions, unless otherwise specified	8-May-13
Equity [Abstract]
Share repurchase program, authorized amount	$50
Stock repurchased amount	$39.50

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	6 Months Ended	1 Months Ended	0 Months Ended
	Jun. 30, 2014	Jan. 31, 2015	Mar. 04, 2015
eNeura Inc [Member]
Subsequent Event [Line Items]
Maturity description of promissory note	The eNeura Note will mature on the earlier of (i) March 4, 2019, or (ii) consummation of the acquisition, unless converted or prepaid at an earlier date.
Scenario, Forecast [Member] | Tempus [Member]
Subsequent Event [Line Items]
Net sales consideration transferred		$2,100,000
Consideration in cash		4,800,000
Scenario, Forecast [Member] | eNeura Inc [Member]
Subsequent Event [Line Items]
Non-refundable fees paid			250,000
Principal amount of promissory note			15,000,000
Accrued interest on promissory note			8.00%
Amount paid to former shareholders			$65,000,000